
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.04fe9e55f2b2.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.aafaa535cb7f.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.ca6dfa7b90b5.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C3473C7F264D500004AB1F63F8FC0.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="1.6.0.post2+24fead6" />

<meta name="ncbi_domain" content="ijms" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10298070/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298070/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="International Journal of Molecular Sciences" /><meta name="citation_title" content="Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes" /><meta name="citation_author" content="Fatih M. Uckun" /><meta name="citation_author" content="Sanjive Qazi" /><meta name="citation_publication_date" content="2023/06" /><meta name="citation_issue" content="12" /><meta name="citation_volume" content="24" /><meta name="citation_doi" content="10.3390/ijms24129943" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10298070/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10298070/" /><meta name="citation_pmid" content="37373090" /><meta name="DC.Title" content="Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Multidisciplinary Digital Publishing Institute  (MDPI)" /><meta name="DC.Contributor" content="Fatih M. Uckun" /><meta name="DC.Contributor" content="Sanjive Qazi" /><meta name="DC.Date" content="2023 Jun" /><meta name="DC.Identifier" content="10.3390/ijms24129943" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes" /><meta property="og:type" content="article" /><meta property="og:description" content="The main goal of the present study was to examine if the RNA-sequencing (RNAseq)-based ERBB2/HER2 expression level in malignant plasma cells from multiple myeloma (MM) patients has clinical significance for treatment outcomes and survival. We examined ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298070/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Int%20J%20Mol%20Sci%22[journal]" class="navlink">Int J Mol Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10298070
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10298070/pdf/ijms-24-09943.pdf" class="int-view">PDF (3.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10298070/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10298070/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10298070" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="gIflmTFVHUF0XOshNJiFn99hFDpc6xrdGqWGr2pV3PEXC1iDD5QcJeOrCVubZf50">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F&amp;text=Upregulated%20Expression%20of%20ERBB2%2FHER2%20in%20Multiple%20Myeloma%20as%20a%20Predictor%20of%20Poor%20Survival%20Outcomes" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298070/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37373090/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37373090/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10298070/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Int%20J%20Mol%20Sci%22[journal]" class="navlink">Int J Mol Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10298070
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-ijms.png" alt="Logo of ijms" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.mdpi.com/journal/ijms/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Int J Mol Sci.</span> 2023 Jun; 24(12): 9943. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Jun 9. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.3390%2Fijms24129943" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3390/ijms24129943</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10298070</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37373090">37373090</a></div></div></div><h1 class="content-title">Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Uckun%20FM%5BAuthor%5D">Fatih M. Uckun</a><sup>*</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Qazi%20S%5BAuthor%5D">Sanjive Qazi</a></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="contrib-group half_rhythm fm-editor">Despina Bazou, <span class="fm-role">Academic Editor</span> and  Paul Dowling, <span class="fm-role">Academic Editor</span></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140629308674288_ai idm140629318798480_ai idm140629309132208_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140629308674288_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140629308674288_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140629308674288_ai" style="display:none"><div class="fm-affl" id="af1-ijms-24-09943">Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA</div><div id="c1-ijms-24-09943"><sup>*</sup>Correspondence: <a href="mailto:dev@null" data-email="moc.timsera@nukcu.hitaf" class="oemail">moc.timsera@nukcu.hitaf</a></div></div><div class="fm-article-notes hide half_rhythm" id="idm140629308674288_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 May 8; Revised 2023 Jun 2; Accepted 2023 Jun 6.</div></div><div class="permissions half_rhythm hide" id="idm140629308674288_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2023 by the authors.</div><div class="license half_rhythm">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">https://creativecommons.org/licenses/by/4.0/</a>).</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div><a href="/pmc/articles/PMC10298070/bin/ijms-24-09943-s001.zip" data-ga-action="click_feat_suppl">ijms-24-09943-s001.zip</a><span style="color:gray"> (914K)</span></div><div class="small guid">GUID: 7815264D-86DC-48C1-A7C9-E2A994E4716F</div></div></dd></dl><dl data-length="1298" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>All data are presented in the manuscript. The publicly available archived databases that were used to generate the data are provided in <a href="#sec2-ijms-24-09943" rid="sec2-ijms-24-09943" class=" sec">Section 2</a>. Gene level RNAseq raw count data (STAR-aligned unstranded number of reads aligned per gene per sample) were downloaded from the archived MMRF CoMMpass dataset by connecting to the GDC portal (<a href="https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf">https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf</a> (accessed on 24 September 2022)) using the Bioconductor package, GenomicDataCommons_1.18.0 (release date 11 August 2021 with full functionality as provided by TCGAbiolinks for accessing GDC data (<a href="https://bioconductor.org/packages/release/bioc/html/GenomicDataCommons.html">https://bioconductor.org/packages/release/bioc/html/GenomicDataCommons.html</a> (accessed on 20 September 2022)) implemented in R version 4.1.2 (1 November 2021). The mRNA expression data were deposited in files appended with &#x0201c;&#x02026;.rna_seq.augmented_star_gene_counts.tsv&#x0201d;. Clinical data for each MM patient were also acquired via functions provided in GenomicDataCommons_1.18.0 and the case IDs were matched with RNAseq unique identifiers utilizing the metadata (&#x0201c;metadata.cart.2022-09-04.json&#x0201d;) from the GDC portal converted into R data by running the utilities rjson_0.2.21 and stringr_1.4.0.</p></dd></dl></div><div id="abstract-a.l.b.p" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.l.b.ptitle">Abstract</h2><!--article-meta--><div><p class="p p-first-last">The main goal of the present study was to examine if the RNA-sequencing (RNAseq)-based ERBB2/HER2 expression level in malignant plasma cells from multiple myeloma (MM) patients has clinical significance for treatment outcomes and survival. We examined the relationship between the RNAseq-based ERBB2 messenger ribonucleic acid (mRNA) levels in malignant plasma cells and survival outcomes in 787 MM patients treated on contemporary standard regimens. ERBB2 was expressed at significantly higher levels than ERBB1 as well as ERBB3 across all three stages of the disease. Upregulated expression of ERBB2 mRNA in MM cells was correlated with amplified expression of mRNAs for transcription factors (TF) that recognize the ERBB2 gene promoter sites. Patients with higher levels of ERBB2 mRNA in their malignant plasma cells experienced significantly increased cancer mortality, shorter progression-free survival, and worse overall survival than other patients. The adverse impact of high ERBB2 expression on patient survival outcomes remained significant in multivariate Cox proportional hazards models that accounted for the effects of other prognostic factors. To the best of our knowledge, this is the first demonstration of an adverse prognostic impact of high-level ERBB2 expression in MM patients. Our results encourage further evaluation of the prognostic significance of high-level ERBB2 mRNA expression and the clinical potential of ERBB2-targeting therapeutics as personalized medicines to overcome cancer drug resistance in high-risk as well as relapsed/refractory MM.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">ERBB2, ERBB1, HER2, EGF, protein tyrosine kinase, multiple myeloma, transcription factor</span></div></div><div id="sec1-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1-ijms-24-09943title">1. Introduction</h2><p class="p p-first">The ERBB receptor family is comprised of four members, namely, epidermal growth factor receptor (EGFR)/ERBB1, Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2/human EGFR 2 (HER2)), Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3), and Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4) [<a href="#B1-ijms-24-09943" rid="B1-ijms-24-09943" class=" bibr popnode">1</a>,<a href="#B2-ijms-24-09943" rid="B2-ijms-24-09943" class=" bibr popnode">2</a>,<a href="#B3-ijms-24-09943" rid="B3-ijms-24-09943" class=" bibr popnode">3</a>,<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>]. ERBB1 signaling plays vital roles in regulating cell proliferation, differentiation, survival, and motility, as well as de-differentiation and malignant transformation in epithelial- or mesenchymal-lineage cells [<a href="#B5-ijms-24-09943" rid="B5-ijms-24-09943" class=" bibr popnode">5</a>,<a href="#B6-ijms-24-09943" rid="B6-ijms-24-09943" class=" bibr popnode">6</a>,<a href="#B7-ijms-24-09943" rid="B7-ijms-24-09943" class=" bibr popnode">7</a>,<a href="#B8-ijms-24-09943" rid="B8-ijms-24-09943" class=" bibr popnode">8</a>,<a href="#B9-ijms-24-09943" rid="B9-ijms-24-09943" class=" bibr popnode">9</a>]. It serves as a receptor for several ligands, such as epidermal growth factor (EGF) and amphiregulin (AREG) [<a href="#B5-ijms-24-09943" rid="B5-ijms-24-09943" class=" bibr popnode">5</a>,<a href="#B6-ijms-24-09943" rid="B6-ijms-24-09943" class=" bibr popnode">6</a>,<a href="#B7-ijms-24-09943" rid="B7-ijms-24-09943" class=" bibr popnode">7</a>,<a href="#B8-ijms-24-09943" rid="B8-ijms-24-09943" class=" bibr popnode">8</a>,<a href="#B9-ijms-24-09943" rid="B9-ijms-24-09943" class=" bibr popnode">9</a>]. Engagement of the ERBB1 by one of its ligands results in the activation of its catalytic protein tyrosine kinase (PTK) function and triggers tyrosine phosphorylation of related ERBB family receptors [<a href="#B1-ijms-24-09943" rid="B1-ijms-24-09943" class=" bibr popnode">1</a>,<a href="#B2-ijms-24-09943" rid="B2-ijms-24-09943" class=" bibr popnode">2</a>,<a href="#B3-ijms-24-09943" rid="B3-ijms-24-09943" class=" bibr popnode">3</a>,<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>,<a href="#B5-ijms-24-09943" rid="B5-ijms-24-09943" class=" bibr popnode">5</a>,<a href="#B6-ijms-24-09943" rid="B6-ijms-24-09943" class=" bibr popnode">6</a>,<a href="#B7-ijms-24-09943" rid="B7-ijms-24-09943" class=" bibr popnode">7</a>,<a href="#B8-ijms-24-09943" rid="B8-ijms-24-09943" class=" bibr popnode">8</a>,<a href="#B9-ijms-24-09943" rid="B9-ijms-24-09943" class=" bibr popnode">9</a>]. ERBB1 is overexpressed and/or intrinsically overactive due to mutations in malignant solid tumors [<a href="#B10-ijms-24-09943" rid="B10-ijms-24-09943" class=" bibr popnode">10</a>,<a href="#B11-ijms-24-09943" rid="B11-ijms-24-09943" class=" bibr popnode">11</a>,<a href="#B12-ijms-24-09943" rid="B12-ijms-24-09943" class=" bibr popnode">12</a>,<a href="#B13-ijms-24-09943" rid="B13-ijms-24-09943" class=" bibr popnode">13</a>,<a href="#B14-ijms-24-09943" rid="B14-ijms-24-09943" class=" bibr popnode">14</a>]. Studies examining ERBB1 and ERBB2 overexpression and/or overactivation demonstrated significant relationships to disease progression, fast invasive growth, and metastatic spread [<a href="#B10-ijms-24-09943" rid="B10-ijms-24-09943" class=" bibr popnode">10</a>,<a href="#B11-ijms-24-09943" rid="B11-ijms-24-09943" class=" bibr popnode">11</a>,<a href="#B12-ijms-24-09943" rid="B12-ijms-24-09943" class=" bibr popnode">12</a>,<a href="#B13-ijms-24-09943" rid="B13-ijms-24-09943" class=" bibr popnode">13</a>,<a href="#B14-ijms-24-09943" rid="B14-ijms-24-09943" class=" bibr popnode">14</a>], as well as resistance to biotherapeutic drugs targeting inhibitor immune checkpoints [<a href="#B15-ijms-24-09943" rid="B15-ijms-24-09943" class=" bibr popnode">15</a>].</p><p>While the expression and function of the epidermal growth factor receptor (EGFR)/ERBB1 has been extensively studied in normal and malignant cells of epithelial and mesenchymal origins, very little is understood regarding its expression in normal or malignant lymphoid cells. However, recent studies indicated that lymphoid cells also express ERBB1 [<a href="#B16-ijms-24-09943" rid="B16-ijms-24-09943" class=" bibr popnode">16</a>,<a href="#B17-ijms-24-09943" rid="B17-ijms-24-09943" class=" bibr popnode">17</a>,<a href="#B18-ijms-24-09943" rid="B18-ijms-24-09943" class=" bibr popnode">18</a>,<a href="#B19-ijms-24-09943" rid="B19-ijms-24-09943" class=" bibr popnode">19</a>,<a href="#B20-ijms-24-09943" rid="B20-ijms-24-09943" class=" bibr popnode">20</a>]. Notably, ERBB1 ligands AREG and EGF have been shown to stimulate the proliferation of multiple myeloma (MM) cells [<a href="#B21-ijms-24-09943" rid="B21-ijms-24-09943" class=" bibr popnode">21</a>,<a href="#B22-ijms-24-09943" rid="B22-ijms-24-09943" class=" bibr popnode">22</a>], and inhibiting ERBB1 caused cytotoxicity to MM cells [<a href="#B23-ijms-24-09943" rid="B23-ijms-24-09943" class=" bibr popnode">23</a>,<a href="#B24-ijms-24-09943" rid="B24-ijms-24-09943" class=" bibr popnode">24</a>]. Our recent studies demonstrated that ERBB1 expression is upregulated in MM cells, and higher levels of ERBB1 are associated with poor treatment outcomes and survival in newly diagnosed MM [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>].</p><p class="p p-last">Although several ligands have been identified for ERBB1, ERBB3, and ERBB4, a specific ligand for the receptor kinase ERBB2 has not been identified [<a href="#B2-ijms-24-09943" rid="B2-ijms-24-09943" class=" bibr popnode">2</a>,<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>]. However, ERBB2/HER2 serves as a co-receptor for other ERBB proteins that is capable of forming heterodimers and thereby facilitating the generation of an amplified intracellular biochemical signal following binding of a specific ligand to the extracellular domain of its heterodimerization partner [<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>]. For example, ERBB1-binding ligands, such as EGF, amphiregulin (AR), and transforming growth factor-&#x003b1; (TGF&#x003b1;) trigger a potent signal after binding to the ERBB1 portion of ERBB1&#x000d7;ERBB2 heterodimers [<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>]. The primary purpose of the present bioinformatics study was to examine if the RNA-sequencing-based ERBB2/HER2 expression level in malignant plasma cells from MM patients has clinical significance for treatment outcomes and survival. To this end, we used the Multiple Myeloma Research Foundation (MMRF)-CoMMpass RNA sequencing (RNAseq) dataset generated in patients treated on contemporary standard regimens. Upregulated expression of ERBB2 in MM cells was correlated with amplified expression of transcription factors (TF) that recognize the ERBB2 gene promoter sites. Notably, high-level ERBB2/HER2 expression was associated with increased cancer mortality and significantly worse overall survival (OS) of MM patients.</p></div><div id="sec2-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2-ijms-24-09943title">2. Results</h2><div id="sec2dot1-ijms-24-09943" class="sec sec-first"><h3 id="sec2dot1-ijms-24-09943title">2.1. ERBB2/HER2 mRNA Is Expressed at Significantly Higher Levels Than EGRF/ERBB1 mRNA and ERBB3 mRNA across All Clinical Stages of MM</h3><p class="p p-first-last">The ERBB2/HER2 gene was abundantly expressed in malignant plasma cells and none of the 766 MM patients with ISS staging information had zero alignments to the ERBB2/HER2 gene (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f001" rid-ob="ob-ijms-24-09943-f001" co-legend-rid="lgnd_ijms-24-09943-f001"><span>Figure 1</span></a>A). No significant differences in ERBB2/HER2 expression levels were observed in the pairwise comparisons between the three stages (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f001" rid-ob="ob-ijms-24-09943-f001" co-legend-rid="lgnd_ijms-24-09943-f001"><span>Figure 1</span></a>B). Notably, the levels for ERBB2/HER2 mRNA in the pooled set of 766 MM patients (Mean &#x000b1; SEM = 7.71 &#x000b1; 0.03) was significantly higher than the levels for ERBB1 mRNA (Mean &#x000b1; SEM = 4.08 &#x000b1; 0.04; <em>t</em>-test, <em>p</em> &#x0003c; 0.0001) or ERBB3 mRNA (Mean &#x000b1; SEM = 4.09 &#x000b1; 0.03; <em>p</em> &#x0003c; 0.0001).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f001" co-legend-rid="lgnd_ijms-24-09943-f001"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f001/" target="figure" rid-figpopup="ijms-24-09943-f001" rid-ob="ob-ijms-24-09943-f001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629308181984"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629308181984"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f001"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f001/" target="figure" rid-figpopup="ijms-24-09943-f001" rid-ob="ob-ijms-24-09943-f001">Figure 1</a></div><!--caption a7--><div class="caption"><p>Expression of EGFR/ERBB1, ERBB2/HER2, and ERBB3 genes in malignant plasma cells from newly diagnosed MM patients. We compared the expression of the log<sub>2</sub>-normalized count values for ERBB1, ERBB2, and ERBB3 mRNA in malignant plasma cells from ISS stage I (<em>n</em> = 267), stage II (<em>n</em> = 276), and stage III MM patients (<em>n</em> = 223). Gene-level normalized, log<sub>2</sub>-transformed STAR-counts were calculated utilizing a generalized linear model that fits STAR-counts to negative binomial distribution using DESeq2_1.34.0, and a variance stabilizing data transformation was performed to account for zero count data for undetected genes using the algorithms provided in the statistical package vsn_3.62.0 implemented in R. (<strong>A</strong>) Depicted are the box plots representing the median expression (horizontal line in the box) in the 75th and 25th quantile box, and the whiskers representing the 3rd quartile + 1.5*(interquartile range) and 1st quartile&#x02014;1.5*(interquartile range) of the expression values for ERBB1, ERBB2, and ERBB3 mRNA in stage I, stage II, and stage III MM patients. Log<sub>2</sub>-transformed STAR-counts are shown as log<sub>2</sub>-normalized counts on the Y-axis. The ERBB1 mRNA levels were recently reported [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>] and they are included here solely for comparison with ERBB2 mRNA levels. We determined the lowest detection level for the normalized, variance-stabilized log<sub>2</sub> count value at which there were zero alignments to the gene (detection level = 2.91 represented by the dashed line). The total number of patients with zero counts (&#x0003e;2.91 log<sub>2</sub>-transformed value) for ERBB1, ERBB2, and ERBB3 expression was 157, 0, and 62, respectively. (<strong>B</strong>) Pairwise comparisons for stage II versus stage I and stage III versus stage I (fold change determined from log<sub>2</sub>-fold difference) were carried across groups using the normalization method in the DESeq2 algorithm (implemented in R) to calculate the Wald statistic and <em>p</em>-values correcting for multiple comparisons.</p></div></div></div></div><div id="sec2dot2-ijms-24-09943" class="sec"><h3 id="sec2dot2-ijms-24-09943title">2.2. ERBB2/HER2 Expression in MM Cells Is Correlated with a Transcriptional Activator and Transcription Factors That Bind to ERBB2 Promoter Sites</h3><p class="p p-first-last">We correlated the mRNA expression levels of ERBB2 in malignant plasma cells from 787 MM patients with the mRNA expression levels of 14 transcription factors known to activate ERBB2 expression [<a href="#B26-ijms-24-09943" rid="B26-ijms-24-09943" class=" bibr popnode">26</a>,<a href="#B27-ijms-24-09943" rid="B27-ijms-24-09943" class=" bibr popnode">27</a>,<a href="#B28-ijms-24-09943" rid="B28-ijms-24-09943" class=" bibr popnode">28</a>,<a href="#B29-ijms-24-09943" rid="B29-ijms-24-09943" class=" bibr popnode">29</a>,<a href="#B30-ijms-24-09943" rid="B30-ijms-24-09943" class=" bibr popnode">30</a>,<a href="#B31-ijms-24-09943" rid="B31-ijms-24-09943" class=" bibr popnode">31</a>,<a href="#B32-ijms-24-09943" rid="B32-ijms-24-09943" class=" bibr popnode">32</a>,<a href="#B33-ijms-24-09943" rid="B33-ijms-24-09943" class=" bibr popnode">33</a>,<a href="#B34-ijms-24-09943" rid="B34-ijms-24-09943" class=" bibr popnode">34</a>], as described in <a href="#sec2-ijms-24-09943" rid="sec2-ijms-24-09943" class=" sec">Section 2</a>. Of these 14 genes, 8 showed statistically significant (<em>p</em> &#x0003c; 0.05 and FDR &#x0003c; 0.05) transcript-level correlation with ERBB2, namely, ETV4, SP1, CEBP, PHF8 (a transcriptional activator), TBP, FOXA1, TFAP2C, and XRCC6 (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f002" rid-ob="ob-ijms-24-09943-f002" co-legend-rid="lgnd_ijms-24-09943-f002"><span>Figure 2</span></a>). The biological or clinical significance of these correlations remains unknown and requires further experimental confirmation.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f002" co-legend-rid="lgnd_ijms-24-09943-f002"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f002/" target="figure" rid-figpopup="ijms-24-09943-f002" rid-ob="ob-ijms-24-09943-f002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629303854784"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629303854784"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f002"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f002/" target="figure" rid-figpopup="ijms-24-09943-f002" rid-ob="ob-ijms-24-09943-f002">Figure 2</a></div><!--caption a7--><div class="caption"><p>ERBB2/HER2 mRNA expression is correlated with the mRNA levels of transcription factors that bind to ERBB2 gene promoter sites. We performed pairwise Pearson correlations between mRNA levels for ERBB2 and 14 candidate TFs using the normalized count data in FPKM-UQ aligned to the reference GRCh38.p0 genome build. (<strong>A</strong>) Correlation coefficients for the 8 TFs that exhibited significant transcript-level correlation with ERBB2 (<em>p</em> &#x0003c; 0.05, FDR &#x0003c; 0.05; ETV4, SP1, CEBP, PHF8, TBP, FOXA1, TFAP2C, and XRCC6) were calculated across 787 MM patients (Corr) and are depicted on the heatmap ranging from positive correlations (red) to negative correlations (blue) and organized according to similarly expressed mRNAs for the TFs. Non-significant correlations are indicated with a black cross in the heat map. (<strong>B</strong>) Correlation coefficients are shown for 8 significantly correlated TFs, of which 5 exhibited highly statistically significant correlations with ERBB2 (<em>p</em> &#x0003c; 10<sup>&#x02212;6</sup>; ETV, SP1, CEBPB, PHF8, and TBP). (<strong>C</strong>) Schematic representations of the transcription factor proteins (ellipses) binding to their respective DNA binding sites (rectangles), and the transcriptional activator, PHF8, are shown for the 8 most significantly positively ERBB2-correlated mRNA levels.</p></div></div></div></div><div id="sec2dot3-ijms-24-09943" class="sec"><h3 id="sec2dot3-ijms-24-09943title">2.3. Amplified ERBB2/HER2 Expression in Malignant Plasma Cells from MM Patients Is Associated with Poor PFS Outcomes</h3><p class="p p-first-last">We first evaluated the potential impact of high-level ERBB2/HER2 mRNA expression on PFS outcome in 669 evaluable MM patients (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S1A</a>). ERBB2<sup>high</sup> patients (i.e., 335 patients with the top 50% of the highest observed expression level for FPKM-UQ aligned to the ERBB2 sequence) had significantly shorter median PFS than ERBB2<sup>low</sup> patients (i.e., 334 patients with the bottom 50% of the expression level for FPKM-UQ aligned to the ERBB2 sequence) (27 months vs. 36 months, log-rank chi-square = 4.85, <em>p</em>-value = 0.028). We confirmed the adverse impact of high ERBB2/HER2 expression on PFS using both univariate and multivariate Cox regression models for 647 evaluable patients (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f003/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f003" rid-ob="ob-ijms-24-09943-f003" co-legend-rid="lgnd_ijms-24-09943-f003"><span>Figure 3</span></a>A). Further, in the multivariate Cox regression model, ERBB2 mRNA expression level as a linear covariate exhibited a significant 1.54-fold increase in the hazard ratio for each unit increase in FPKM-UQ counts (<em>p</em> &#x0003c; 0.001) that persisted with the inclusion of other prognostic factors, including ISS stage, age, as well as serum albumin and beta 2 microglobulin levels (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S1B</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f003" co-legend-rid="lgnd_ijms-24-09943-f003"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f003/" target="figure" rid-figpopup="ijms-24-09943-f003" rid-ob="ob-ijms-24-09943-f003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629316553504"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629316553504"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f003"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f003/" target="figure" rid-figpopup="ijms-24-09943-f003" rid-ob="ob-ijms-24-09943-f003">Figure 3</a></div><!--caption a7--><div class="caption"><p>The unfavorable impact of high HER2/ERBB2 expression on PFS and OS outcomes of MM patients from the MMRF-CoMMpass study in univariate and multivariate Cox proportional hazards models. Normalized expression levels of ERRB2 (FPKM-UQ) were correlated with PFS (Panels (<strong>A</strong>,<strong>B</strong>)) and OS (Panels (<strong>C</strong>,<strong>D</strong>)) times using the univariate and multivariate Cox proportional hazards models. We investigated 2 categorical variables: (i) ERBB2 expression (i.e., ERBB2 high expression, the top 50% of patients versus ERBB2 low expression, the bottom 50% of patients) and (ii) ISS prognostic stage (ISS Stage), and 3 linear co-variates (age, serum beta 2 microglobulin levels, and serum albumin levels). Depicted in (<strong>A</strong>,<strong>C</strong>) are the forest plots along with the corresponding HRs and <em>p</em>-values for each covariate. The tables in (<strong>B</strong>,<strong>D</strong>) compare the effect of each variable considering univariate and multivariate applications of the Cox proportional hazards model. Significant <em>p</em>-values are indicated by *, **, and *** for <em>p</em> &#x0003c; 0.05, <em>p</em> &#x0003c; 0.01, and <em>p</em> &#x0003c; 0.001, respectively. (<strong>A</strong>,<strong>B</strong>) Comparison of the PFS times for 647 evaluable patients showed a significant increase in HR for patients with high expression of ERBB2 compared with patients with low ERBB2 expression in the multivariate model. The comparison of the multivariate model with the univariate testing of each of these variables showed that the increased HR observed in patients with high levels of ERBB2 was similar in both models: univariate model HR = 1.29 (1.06&#x02013;1.58) versus multivariate model HR = 1.35 (1.1&#x02013;1.66). (<strong>C</strong>,<strong>D</strong>) OS relationships were evaluable for 767 MM patients. The multivariate model exhibited an increase in HR for patients expressing high levels of ERBB2 (HR = 1.76 (1.27&#x02013;2.45)) that was similar to the HR of 1.89 (1.35&#x02013;2.63) in the univariate model (<strong>D</strong>).</p></div></div></div></div><div id="sec2dot4-ijms-24-09943" class="sec"><h3 id="sec2dot4-ijms-24-09943title">2.4. Amplified ERBB2/HER2 Expression in Malignant Plasma Cells from MM Patients Is Associated with Poor OS</h3><p class="p p-first">We next sought to determine the effect of amplified ERBB2/HER2 mRNA expression on OS in 787 MM patients considering all deaths from any cause in our analysis. ERBB2<sup>high</sup> patients (i.e., 394 patients with the top 50% of the highest observed expression level for FPKM-UQ aligned to the ERBB2 sequence) had a significantly shorter OS than ERBB2<sup>low</sup> patients (i.e., 393 patients with the bottom 50% of the observed expression level for FPKM-UQ aligned to the ERBB2 sequence) had significantly worse OS outcomes. The cumulative proportion of ERBB2<sup>high</sup> patients remaining alive at 60 months was 50.1 &#x000b1; 6.7%, whereas the cumulative proportion of ERBB2<sup>low</sup> patients remaining alive at 60 months was 69.5 &#x000b1; 7.2% (log-rank chi-square = 8.82, <em>p</em>-value = 0.003) (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f004" rid-ob="ob-ijms-24-09943-f004" co-legend-rid="lgnd_ijms-24-09943-f004"><span>Figure 4</span></a>A). We confirmed the adverse impact of high ERBB2 expression on OS using both univariate and multivariate Cox regression models for 767 evaluable patients (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f003/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f003" rid-ob="ob-ijms-24-09943-f003" co-legend-rid="lgnd_ijms-24-09943-f003"><span>Figure 3</span></a>B). Further, in the multivariate Cox regression model, ERBB2 mRNA expression level as a linear covariate exhibited a significant two-fold increase in the hazard ratio for each unit increase in FPKM-UQ counts (<em>p</em> &#x0003c; 0.001) that persisted with the inclusion of other prognostic factors, including ISS stage, age, as well as serum albumin and beta 2 microglobulin levels (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f004" rid-ob="ob-ijms-24-09943-f004" co-legend-rid="lgnd_ijms-24-09943-f004"><span>Figure 4</span></a>B).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f004" co-legend-rid="lgnd_ijms-24-09943-f004"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f004/" target="figure" rid-figpopup="ijms-24-09943-f004" rid-ob="ob-ijms-24-09943-f004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629308049344"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629308049344"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f004/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f004"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f004/" target="figure" rid-figpopup="ijms-24-09943-f004" rid-ob="ob-ijms-24-09943-f004">Figure 4</a></div><!--caption a7--><div class="caption"><p>Higher expression levels of HER2/ERBB2 in malignant plasma cells from MM patients are associated with shorter OS. (<strong>A</strong>) Depicted for comparison are the OS curves for 394 ERBB2<sup>high</sup> MM patients (i.e., patients with the top 50% of the highest observed expression level for FPKM-UQ aligned to the ERBB2 sequence) and 393 ERBB2<sup>low</sup> MM patients (i.e., patients with the bottom 50% with the lowest observed expression level for FPKM-UQ aligned to the ERBB2 sequence). Cumulative proportions surviving at 60 mo: 50.1 &#x000b1; 6.7% for ERBB2<sup>high</sup> and 69.5 &#x000b1; 7.2% for ERBB2<sup>low</sup>. (<strong>B</strong>) Depicted is the forest plot comparing the HRs for each covariate included in a multivariate Cox proportional hazards model, namely, ERBB2 mRNA level, ISS stage, age, as well as serum albumin and beta 2 microglobulin levels in 767 evaluable patients. ERBB2 mRNA expression level exhibited a significant 1.96-fold increase in the hazard ratio for each unit increase in FPKM-UQ counts (<em>p</em> &#x0003c; 0.001). Significant <em>p</em>-values are indicated by *, **, and *** for <em>p</em> &#x0003c; 0.05, <em>p</em> &#x0003c; 0.01, and <em>p</em> &#x0003c; 0.001, respectively.</p></div></div></div><p class="p p-last">We next assessed the OS of four distinct patient groups defined by co-expression levels of ERBB2 and ERBB1: (i) ERBB1<sup>high</sup>/ERBB2<sup>high</sup> (top 50th percentile of the highest observed expression levels for both ERBB1 and ERBB2 mRNA expression levels) (<em>n</em> = 195), (ii) ERBB1<sup>low</sup>/ERBB2<sup>low</sup> (bottom 50th percentile of the lowest observed expression levels for both ERBB1 and ERBB2 (<em>n</em> = 194), (iii) ERBB1<sup>low</sup>/ERBB2<sup>high</sup> (<em>n</em> = 199), and (iv) ERBB1<sup>high</sup>/ERBB2<sup>low</sup>(<em>n</em> = 199). ERBB1<sup>low</sup>/ERBB2<sup>low</sup> patients representing 24.7% of the 787 evaluable patients had significantly fewer deaths and consequently the best 5-year survival of 83.3% when compared to the remaining three groups of patients (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S2</a>).</p></div><div id="sec2dot5-ijms-24-09943" class="sec"><h3 id="sec2dot5-ijms-24-09943title">2.5. Amplified ERBB2/HER2 Expression in Malignant Plasma Cells from MM Patients Is Associated with Increased Cancer-Related Mortality</h3><p class="p p-first">We next evaluated the potential impact of high-level ERBB2/HER2 mRNA expression on cancer-related mortality (CRM) in 716 evaluable MM patients (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S3A</a>). ERBB2<sup>high</sup> patients (i.e., 358 patients with the top 50% of the observed expression level for FPKM-UQ aligned to the ERBB2 sequence) had a significantly higher CRM than ERBB2<sup>low</sup> patients (i.e., 358 patients with the bottom 50% of the observed expression level for FPKM-UQ aligned to the ERBB2 sequence) (37.3 &#x000b1; 7.2% vs. 22.7 &#x000b1; 8.5%; log-rank chi-square = 6.17, <em>p</em>-value = 0.013). We confirmed the adverse impact of high ERBB2 expression on CRM using a multivariate Cox regression model for 695 evaluable patients. ERBB2 mRNA expression level as a linear covariate exhibited a significant 2.23-fold increase in the hazard ratio for each unit increase in FPKM-UQ counts (<em>p</em> &#x0003c; 0.001) that persisted with the inclusion of other prognostic factors, including ISS stage, age, as well as serum albumin and beta 2 microglobulin levels (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S3B</a>).</p><p class="p p-last">We next assessed the CRM of four distinct patient groups defined by co-expression levels of ERBB2 and ERBB1: (i) ERBB1<sup>high</sup>/ERBB2<sup>high</sup> (the top 50% of the observed expression levels for both ERBB1 and ERBB2 mRNA expression levels) (<em>n</em> = 181), (ii) ERBB1<sup>low</sup>/ERBB2<sup>low</sup> (the bottom 50% of the observed expression levels for both ERBB1 and ERBB2 (<em>n</em> = 181), (iii) ERBB1<sup>low</sup>/ERBB2<sup>high</sup> (<em>n</em> = 177), and (iv) ERBB1<sup>high</sup>/ERBB2<sup>low</sup>(<em>n</em> = 177). ERBB1<sup>low</sup>/ERBB2<sup>low</sup> patients representing 25.3% of the 716 evaluable patients had significantly fewer cancer-related deaths and, consequently, the lowest 5-year CRM (7.2 &#x000b1; 2.1%) when compared with the remaining three groups of patients (5-year CRM: ERBB1<sup>high</sup>/ERBB2<sup>high</sup> = 39.4 &#x000b1; 10%, ERBB1<sup>high</sup>/ERBB2<sup>low</sup> = 38.1 &#x000b1; 14.4%, and ERBB1<sup>low</sup>/ERBB2<sup>high</sup> = 33.8 &#x000b1; 9%) (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S4</a>).</p></div><div id="sec2dot6-ijms-24-09943" class="sec sec-last"><h3 id="sec2dot6-ijms-24-09943title">2.6. A STRING Model of HER2/ERBB2-Regulated Signaling Network Reveals 8 ERBB2-Associated Signaling Molecules as Poor OS Indicators</h3><p class="p p-first-last">We compared the OS outcomes curves for 394 MM patients with high levels of mRNA expression for ERBB2 and associated genes coding for proteins associated with ERBB2 (i.e., patients with the top 50% of the observed expression level for FPKM-UQ values for each gene) with the OS outcomes of 393 MM patients with low mRNA expression levels for each gene (i.e., patients with the bottom 50% of the observed expression level for FPKM-UQ values). Depicted in <a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f005" rid-ob="ob-ijms-24-09943-f005" co-legend-rid="lgnd_ijms-24-09943-f005"><span>Figure 5</span></a> are ERBB2 and 15 additional genes in the STRING network exhibiting prognostic significance. ERBB2 exhibited direct associations with SHC1, CBL, PTPN11, FYN, KRAS, HRAS, NRAS, and MAP2K1 (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f005" rid-ob="ob-ijms-24-09943-f005" co-legend-rid="lgnd_ijms-24-09943-f005"><span>Figure 5</span></a>). Three signaling molecules exhibited the most significant increases in hazard ratios at augmented expression levels, namely, EIF4EBP1 (HR = 1.84; <em>p</em> = 0.0001), PTPN11 (HR = 1.81; <em>p</em> = 0.0002), and MAP2K1 (HR = 1.67; <em>p</em> = 0.0011) (<a href="/pmc/articles/PMC10298070/table/ijms-24-09943-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-t001" rid-ob="ob-ijms-24-09943-t001" co-legend-rid=""><span>Table 1</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f005" co-legend-rid="lgnd_ijms-24-09943-f005"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/" target="figure" rid-figpopup="ijms-24-09943-f005" rid-ob="ob-ijms-24-09943-f005"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629312688112"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g005.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g005.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629312688112"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f005"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/" target="figure" rid-figpopup="ijms-24-09943-f005" rid-ob="ob-ijms-24-09943-f005">Figure 5</a></div><!--caption a7--><div class="caption"><p>Higher expression levels of HER2/ERBB2 and a highly connected network of genes coding for signaling proteins in malignant plasma cells from MM patients are associated with worse OS outcomes. Depicted is a model STRING network comprised of ERBB2 and 15 other signaling molecules with poor survival associated with their high-level mRNA expression. The networked associations were calculated using the strength of evidence from experiments, databases, and co-expression using the STRING algorithm (STRING11.5 algorithm (<a href="http://string-db.org/">http://string-db.org/</a>). Clustering was conducted on the association scores to group protein&#x02013;protein interaction networks using the MCL algorithm provided via the STRING software showing solid lines representing connections within the 2 detected clusters and dotted lines connecting between clusters. The network graph illustrates 16 nodes with 49 edges which were significantly higher than the expected number of 8 edges (<em>p</em> &#x0003c; 0.0001) based on a random set of proteins of the same size and degree of distribution drawn from the genome, suggesting that this highly connected set of nodes is biologically meaningful. In this network graph, ERBB2 exhibited direct associations with 8 genes coding for proteins, namely, SHC1, CBL, PTPN11, FYN, KRAS, HRAS, NRAS, and MAP2K1, and an additional 7 genes with associations in the second shell of this network: EIF4EBP1; MTOR; FGR; FKBP1A; RALA; CRKL; and RPS6KB1.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="ijms-24-09943-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>ERBB2-associated signaling molecules as poor OS indicators.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Signaling Molecule</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Log-Rank<br />Chi-Square Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><em>p</em>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">EIF4EBP1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.84 (1.34&#x02013;2.53)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PTPN11</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81 (1.31&#x02013;2.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MAP2K1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67 (1.23&#x02013;2.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ERBB2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.61 (1.17&#x02013;2.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.82</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0030</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FYN</td><td align="center" valign="middle" rowspan="1" colspan="1">1.58 (1.16&#x02013;2.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0039</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MTOR</td><td align="center" valign="middle" rowspan="1" colspan="1">1.56 (1.13&#x02013;2.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0057</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SHC1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 (1.13&#x02013;2.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.43</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0064</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KRAS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53 (1.12&#x02013;2.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0067</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FGR</td><td align="center" valign="middle" rowspan="1" colspan="1">1.48 (1.09&#x02013;2.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0127</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FKBP1A</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49 (1.08&#x02013;2.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0132</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRAS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 (1.07&#x02013;1.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0158</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HRAS</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 (1.07&#x02013;1.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0166</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CBL</td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 (1.06&#x02013;2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0185</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RALA</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42 (1.04&#x02013;1.94)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0269</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRKL</td><td align="center" valign="middle" rowspan="1" colspan="1">1.38 (1.01&#x02013;1.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0422</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPS6KB1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36 (1&#x02013;1.86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0471</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140629312681616"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/table/ijms-24-09943-t001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.o.g.e.a"><p class="p p-first-last">EIF4EBP1: eukaryotic translation initiation factor 4E-binding protein 1; PTPN11: tyrosine-protein phosphatase non-receptor type 11; MAP2K1: dual specificity mitogen-activated protein kinase kinase 1/MEK1; ERBB2: receptor tyrosine-protein kinase erbB-2; FYN: tyrosine-protein kinase Fyn; MTOR: serine/threonine-protein kinase mTOR; SHC1: SHC-transforming protein 1; KRAS: GTPase KRas; FGR: Fgr proto-oncogene, Src family tyrosine kinase; FKBP1A: peptidyl-prolyl cis&#x02013;trans isomerase; NRAS: Nras proto-oncogene, gtpase; HRAS: GTPase HRas; CBL: E3 ubiquitin-protein ligase CBL; RALA: Ras-related protein Ral-A; CRKL: Crk-like protein; and RPS6KB1: ribosomal protein S6 kinase beta-1.</p></div></div></div></div></div><div id="sec3-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3-ijms-24-09943title">3. Discussion</h2><p class="p p-first">Contemporary treatment strategies for multiple myeloma (MM) still fail in a significant portion of patients due to the emergence of resistance in MM clones to active anti-MM drugs [<a href="#B35-ijms-24-09943" rid="B35-ijms-24-09943" class=" bibr popnode">35</a>,<a href="#B36-ijms-24-09943" rid="B36-ijms-24-09943" class=" bibr popnode">36</a>,<a href="#B37-ijms-24-09943" rid="B37-ijms-24-09943" class=" bibr popnode">37</a>,<a href="#B38-ijms-24-09943" rid="B38-ijms-24-09943" class=" bibr popnode">38</a>,<a href="#B39-ijms-24-09943" rid="B39-ijms-24-09943" class=" bibr popnode">39</a>,<a href="#B40-ijms-24-09943" rid="B40-ijms-24-09943" class=" bibr popnode">40</a>,<a href="#B41-ijms-24-09943" rid="B41-ijms-24-09943" class=" bibr popnode">41</a>]. Effective treatments capable of preventing or overcoming cancer drug resistance are urgently needed [<a href="#B35-ijms-24-09943" rid="B35-ijms-24-09943" class=" bibr popnode">35</a>,<a href="#B36-ijms-24-09943" rid="B36-ijms-24-09943" class=" bibr popnode">36</a>,<a href="#B37-ijms-24-09943" rid="B37-ijms-24-09943" class=" bibr popnode">37</a>,<a href="#B38-ijms-24-09943" rid="B38-ijms-24-09943" class=" bibr popnode">38</a>,<a href="#B39-ijms-24-09943" rid="B39-ijms-24-09943" class=" bibr popnode">39</a>,<a href="#B40-ijms-24-09943" rid="B40-ijms-24-09943" class=" bibr popnode">40</a>,<a href="#B41-ijms-24-09943" rid="B41-ijms-24-09943" class=" bibr popnode">41</a>]. The tumor microenvironment (TME) in MM has been shown to play a pivotal role in disease progression by facilitating the immune escape of MM cells via both immune suppression and activation of signaling pathways that prevent apoptosis and stimulate their proliferation [<a href="#B42-ijms-24-09943" rid="B42-ijms-24-09943" class=" bibr popnode">42</a>,<a href="#B43-ijms-24-09943" rid="B43-ijms-24-09943" class=" bibr popnode">43</a>,<a href="#B44-ijms-24-09943" rid="B44-ijms-24-09943" class=" bibr popnode">44</a>,<a href="#B45-ijms-24-09943" rid="B45-ijms-24-09943" class=" bibr popnode">45</a>,<a href="#B46-ijms-24-09943" rid="B46-ijms-24-09943" class=" bibr popnode">46</a>,<a href="#B47-ijms-24-09943" rid="B47-ijms-24-09943" class=" bibr popnode">47</a>,<a href="#B48-ijms-24-09943" rid="B48-ijms-24-09943" class=" bibr popnode">48</a>]. The immunosuppressive cellular elements of the TME in MM include regulatory T cells (Tregs), regulatory B cells (Bregs), and myeloid-derived suppressor cells (MDSC), whereas the humoral elements include several growth factors and cytokines such as IL-10 that activates Tregs and M2 macrophages and TGF-&#x003b2; which inhibits cytotoxic T-cells and NK cells [<a href="#B42-ijms-24-09943" rid="B42-ijms-24-09943" class=" bibr popnode">42</a>,<a href="#B43-ijms-24-09943" rid="B43-ijms-24-09943" class=" bibr popnode">43</a>,<a href="#B44-ijms-24-09943" rid="B44-ijms-24-09943" class=" bibr popnode">44</a>,<a href="#B45-ijms-24-09943" rid="B45-ijms-24-09943" class=" bibr popnode">45</a>,<a href="#B46-ijms-24-09943" rid="B46-ijms-24-09943" class=" bibr popnode">46</a>,<a href="#B47-ijms-24-09943" rid="B47-ijms-24-09943" class=" bibr popnode">47</a>,<a href="#B48-ijms-24-09943" rid="B48-ijms-24-09943" class=" bibr popnode">48</a>,<a href="#B49-ijms-24-09943" rid="B49-ijms-24-09943" class=" bibr popnode">49</a>]. Several cytokines and growth factors are abundantly produced in the TME of MM patients, including the ERBB1 ligands EGF, TGF-&#x003b1;, and AR, and cause activation of signal transduction pathways that have been implicated in the proliferation, prolonged survival, and dissemination of MM cells [<a href="#B50-ijms-24-09943" rid="B50-ijms-24-09943" class=" bibr popnode">50</a>,<a href="#B51-ijms-24-09943" rid="B51-ijms-24-09943" class=" bibr popnode">51</a>,<a href="#B52-ijms-24-09943" rid="B52-ijms-24-09943" class=" bibr popnode">52</a>,<a href="#B53-ijms-24-09943" rid="B53-ijms-24-09943" class=" bibr popnode">53</a>,<a href="#B54-ijms-24-09943" rid="B54-ijms-24-09943" class=" bibr popnode">54</a>,<a href="#B55-ijms-24-09943" rid="B55-ijms-24-09943" class=" bibr popnode">55</a>,<a href="#B56-ijms-24-09943" rid="B56-ijms-24-09943" class=" bibr popnode">56</a>]. New therapeutic strategies targeting the TME in MM are being explored in preclinical and clinical settings [<a href="#B42-ijms-24-09943" rid="B42-ijms-24-09943" class=" bibr popnode">42</a>,<a href="#B43-ijms-24-09943" rid="B43-ijms-24-09943" class=" bibr popnode">43</a>,<a href="#B44-ijms-24-09943" rid="B44-ijms-24-09943" class=" bibr popnode">44</a>,<a href="#B45-ijms-24-09943" rid="B45-ijms-24-09943" class=" bibr popnode">45</a>,<a href="#B46-ijms-24-09943" rid="B46-ijms-24-09943" class=" bibr popnode">46</a>,<a href="#B47-ijms-24-09943" rid="B47-ijms-24-09943" class=" bibr popnode">47</a>,<a href="#B48-ijms-24-09943" rid="B48-ijms-24-09943" class=" bibr popnode">48</a>,<a href="#B49-ijms-24-09943" rid="B49-ijms-24-09943" class=" bibr popnode">49</a>].</p><p>ERBB2/HER2 serves as a co-receptor for ERBB1 and as a heterodimer with ERBB1 contributing to the generation of an amplified intracellular biochemical signal after binding of an ERBB1 ligand to the ERBB1 portion of the ERBB1&#x000d7;ERBB2 heterodimer [<a href="#B4-ijms-24-09943" rid="B4-ijms-24-09943" class=" bibr popnode">4</a>]. Upregulated ERBB2/HER2 expression could contribute to the formation of ERBB1&#x000d7;ERBB2 heterodimers and thereby potentiate the ability of ERBB1 ligands in the MM TME, such as EGF and AR to promote the survival, proliferation, and dissemination of MM cells. Patients with higher levels of ERBB2 mRNA in their malignant plasma cells experienced significantly increased CRM, shorter PFS, and worse OS than other patients. The adverse impact of high ERBB2/HER2 expression on patient survival outcomes remained significant in multivariate Cox proportional hazards models that accounted for the effects of other prognostic factors.</p><p>In MM cells with low-level ERBB1 expression unlikely to form ERBB1xERBB1 homodimers abundantly, abundant expression of ERBB2 could compensate for the low-level ERBB1 expression by enabling the formation of ERBB1&#x000d7;ERBB2 heterodimers. It is noteworthy that the CRM of ERBB1<sup>low</sup>ERBB2<sup>high</sup> patients was as high as the CRM of ERBB1<sup>high</sup> patients with low or high ERBB2 levels (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S4</a>). We propose a model according to which ERBB1 signals transmitted by activated ERBB1&#x000d7;ERBB1 homodimers or ERBB1&#x000d7;ERBB2 heterodimers contribute to the demonstrated adverse prognostic effects of ERBB1 [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>] and ERBB2/HER2 (present study) in MM (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f006/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f006" rid-ob="ob-ijms-24-09943-f006" co-legend-rid="lgnd_ijms-24-09943-f006"><span>Figure 6</span></a>). ERBB2 exhibited direct links with eight signaling molecules that were associated with significant increases in hazard ratios for poor OS (<a href="/pmc/articles/PMC10298070/table/ijms-24-09943-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-t001" rid-ob="ob-ijms-24-09943-t001" co-legend-rid=""><span>Table 1</span></a>, <a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f005/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f005" rid-ob="ob-ijms-24-09943-f005" co-legend-rid="lgnd_ijms-24-09943-f005"><span>Figure 5</span></a>). In agreement with such a model, ERBB1<sup>lowand</sup> ERBB2<sup>low</sup> patients whose MM cells would be less likely to form biologically meaningful quantities or ERBB1xERBB1 homodimers or ERBB1&#x000d7;ERBB2 heterodimers had the lowest 5-year cancer-related mortality (7.2 &#x000b1; 2.1%) when compared with the remaining patients (<a href="#app1-ijms-24-09943" rid="app1-ijms-24-09943" class=" app">Figure S4</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-09943-f006" co-legend-rid="lgnd_ijms-24-09943-f006"><a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f006/" target="figure" rid-figpopup="ijms-24-09943-f006" rid-ob="ob-ijms-24-09943-f006"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140629312684704"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10298070_ijms-24-09943-g006.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-09943-g006.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10298070/bin/ijms-24-09943-g006.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140629312684704"><a target="object" rel="noopener" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f006/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-09943-f006"><div><a class="figpopup" href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f006/" target="figure" rid-figpopup="ijms-24-09943-f006" rid-ob="ob-ijms-24-09943-f006">Figure 6</a></div><!--caption a7--><div class="caption"><p>Amplified HER2/ERBB2 expression and directly associated signaling molecules identified via the STRING algorithm resulting in poor overall survival in MM patients. The HER2/ERBB2 receptor (blue symbol) does not bind to the ligands but dimerizes with the EGFR/ERBB1 receptor (red symbol) to activate downstream signal transduction pathways. Dimers of EGFR/ERBB1 bind to EGFR/ERBB1 ligands (green circle; a select group of ligands shown in the green box including EGF, amphiregulin (AREG), transforming growth factor-alpha (TGF&#x003b1;), and heparin-binding EGF-like growth factor (HB-EGF)) to send signals into the cell. Depicted are the 8 signaling molecules directly associated with ERBB2 from the proposed interaction network identified via the STRING algorithm that also exhibited poor OS outcomes at high levels of mRNA expression.</p></div></div></div><p>Several ERBB2/HER-2 targeting therapeutics have been approved for the treatment of solid tumors, such as breast cancer and lung cancer [<a href="#B57-ijms-24-09943" rid="B57-ijms-24-09943" class=" bibr popnode">57</a>,<a href="#B58-ijms-24-09943" rid="B58-ijms-24-09943" class=" bibr popnode">58</a>,<a href="#B59-ijms-24-09943" rid="B59-ijms-24-09943" class=" bibr popnode">59</a>]. Targeting ERBB2 with FDA-approved small molecule ERBB2 inhibitors as well as monoclonal antibodies could potentially improve the treatment options for high-risk or relapsed/refractory (R/R) MM patients. Our results presented herein warrant further examination of the therapeutic potential of already FDA-approved small molecule inhibitors as well as monoclonal antibodies targeting ERBB2 that could be repurposed for use in high-risk or R/R MM. The evaluation of the clinical potential of ERBB2/HER-2 targeting therapeutics, including monoclonal antibodies trastuzumab and pertuzumab, antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan, and small molecule TKI tucatinib alone and in combination with standard anti-MM drugs, as well as ERBB1-targeting antibodies and TKI, would seem warranted. The dual function of TKI neratinib and palatinib inhibit both ERBB1 and ERBB2 and may have clinical potential for high-risk or R/R MM patients.</p><p>In this study, we demonstrated that ERBB2/HER2 co-receptor mRNA was expressed in malignant plasma cells from MM patients at significantly higher levels than ERBB1 as well as ERBB3 across all three stages of the disease. We tested the hypothesis that the amplified ERBB2 mRNA levels in MM cells may be driven by increased expression of specific TFs that transcriptionally activate ERBB2 expression. Our findings demonstrated for the first time that increased ERBB2 mRNA expression shows statistically significant correlations with upregulated mRNA levels of several such TFs, including ETV, SP1, CEBPB, PHF8, and TBP. We propose a model according to which the observed upregulation of ERB2/HER2 mRNA expression in MM cells is driven transcriptionally by several TFs (<a href="/pmc/articles/PMC10298070/figure/ijms-24-09943-f002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-09943-f002" rid-ob="ob-ijms-24-09943-f002" co-legend-rid="lgnd_ijms-24-09943-f002"><span>Figure 2</span></a>C). The presented data expand our current knowledge regarding the networks of signaling pathways affecting the biology and clinical outcome of MM as well as emerging new molecular targets for chemotherapy-drug-resistant MM [<a href="#B60-ijms-24-09943" rid="B60-ijms-24-09943" class=" bibr popnode">60</a>,<a href="#B61-ijms-24-09943" rid="B61-ijms-24-09943" class=" bibr popnode">61</a>,<a href="#B62-ijms-24-09943" rid="B62-ijms-24-09943" class=" bibr popnode">62</a>,<a href="#B63-ijms-24-09943" rid="B63-ijms-24-09943" class=" bibr popnode">63</a>,<a href="#B64-ijms-24-09943" rid="B64-ijms-24-09943" class=" bibr popnode">64</a>,<a href="#B65-ijms-24-09943" rid="B65-ijms-24-09943" class=" bibr popnode">65</a>,<a href="#B66-ijms-24-09943" rid="B66-ijms-24-09943" class=" bibr popnode">66</a>,<a href="#B67-ijms-24-09943" rid="B67-ijms-24-09943" class=" bibr popnode">67</a>,<a href="#B68-ijms-24-09943" rid="B68-ijms-24-09943" class=" bibr popnode">68</a>,<a href="#B69-ijms-24-09943" rid="B69-ijms-24-09943" class=" bibr popnode">69</a>].</p><p class="p p-last">Our hypothesis-generating study suffers from a number of limitations including its primary focus on bioinformatics-based analyses without integrated laboratory testing of ERBB2 mRNA levels using other methods in addition to RNAseq and lack of data to show that MM cells from ERBB2<sup>high</sup> patients with high levels of ERBB2 mRNA also express ERBB2 protein at higher levels than ERBB2<sup>low</sup> patients. Our results need to be verified in a prospective hypothesis-testing study with integrated RNAseq and biochemical testing in a large MM patient population. A multivariate analysis of the prognostic significance of ERBB2 overexpression in relationship to other prognostic factors and especially patient treatment will be very important.</p></div><div id="sec4-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4-ijms-24-09943title">4. Materials and Methods</h2><div id="sec4dot1-ijms-24-09943" class="sec sec-first"><h3 id="sec4dot1-ijms-24-09943title">4.1. Processing and Analysis of the Multiple Myeloma Research Foundation (MMRF)-CoMMpass RNA Sequencing (RNAseq) Dataset</h3><p class="p p-first">The processing of the MMRF-CoMMpass RNAseq dataset was performed, as previously detailed [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]. Pre-processed RNAseq data files for 787 cases used in our analysis are accessible via the GDC portal (<a href="https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf">https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf</a>, accessed on 20 March 2023). The analytical path for RNAseq datasets employed standardized mRNA quantification techniques to enable meta-analysis across multiple projects, as previously described in detail [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]. We utilized the latest version of the RNAseq STAR-quantified data for all 787 cases performed on the GDC portal (<a href="https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf">https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf</a>, accessed on 20 March 2023, release date: 29 March 2022, version 32). STAR-aligned read groups were quantified using the two-pass method that generated the final alignments onto the GRCh38.p0 reference genome to calculate the gene-level RNAseq raw STAR-count data (i.e., STAR-aligned unstranded number of reads aligned per gene per sample), and fragments per kilobase of transcript per million mapped reads (FPKM) normalized to the upper quartile FPKM (FPKM-UQ). Gene expression profiles were downloaded from the archived MMRF CoMMpass dataset, as previously reported [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>].</p><p>Patient-level clinical data were processed via functional tools provided in GenomicDataCommons_1.18.0 and the case IDs were matched with RNAseq unique identifiers utilizing the metadata (&#x0201c;metadata.cart.2022-09-04.json&#x0201d;) from the GDC portal converted into R data by running the utilities rjson_0.2.21 and stringr_1.4.0. The database included 766 ISS-staged patients, including 267 stage I, 276 stage II, and 223 stage III patients. We compared the mRNA expression levels for EGFR/ERBB1, ERBB2/HER2, and ERBB3 in each subset using the DESeq2 package (DESeq2_1.34.0 implemented using R version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria. (1 November 2021)) [<a href="#B70-ijms-24-09943" rid="B70-ijms-24-09943" class=" bibr popnode">70</a>]. Gene-level normalized, log<sub>2</sub>-transformed STAR-counts were calculated utilizing a generalized linear model that fits STAR-counts to negative binomial distribution to approximate the empirical distribution of the count data [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>,<a href="#B70-ijms-24-09943" rid="B70-ijms-24-09943" class=" bibr popnode">70</a>]. Statistical significance was assessed by testing the null hypothesis that there is no differential expression across the two sample groups (Log<sub>2</sub> fold change = 0) using the Wald test [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>,<a href="#B70-ijms-24-09943" rid="B70-ijms-24-09943" class=" bibr popnode">70</a>] reporting the test statistic and <em>p</em>-value for each gene. Genes were considered differentially expressed if the <em>p</em>-values were less than 0.05 after adjusting for multiple comparisons using the Benjamini and Hochberg method [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>,<a href="#B70-ijms-24-09943" rid="B70-ijms-24-09943" class=" bibr popnode">70</a>,<a href="#B71-ijms-24-09943" rid="B71-ijms-24-09943" class=" bibr popnode">71</a>]. To visualize the gene expression levels in box plots, the normalized log<sub>2</sub> values were calculated from the RNAseq count data using the variance stabilization method supplied by the algorithms in vsn_3.62.0 [<a href="#B72-ijms-24-09943" rid="B72-ijms-24-09943" class=" bibr popnode">72</a>]. Pairwise t-tests were performed to compare the expression of ERBB1 vs. ERBB2 and ERBB3 vs. ERBB2 across 766 patients and corrected for multiple comparisons using the Benjamini and Hochberg method.</p><p>We correlated the mRNA expression levels of ERBB2/HER2 in malignant plasma cells from 787 MM patients with the mRNA expression levels of 14 transcription factors known to activate ERBB2 expression [<a href="#B26-ijms-24-09943" rid="B26-ijms-24-09943" class=" bibr popnode">26</a>,<a href="#B27-ijms-24-09943" rid="B27-ijms-24-09943" class=" bibr popnode">27</a>,<a href="#B28-ijms-24-09943" rid="B28-ijms-24-09943" class=" bibr popnode">28</a>,<a href="#B29-ijms-24-09943" rid="B29-ijms-24-09943" class=" bibr popnode">29</a>,<a href="#B30-ijms-24-09943" rid="B30-ijms-24-09943" class=" bibr popnode">30</a>,<a href="#B31-ijms-24-09943" rid="B31-ijms-24-09943" class=" bibr popnode">31</a>,<a href="#B32-ijms-24-09943" rid="B32-ijms-24-09943" class=" bibr popnode">32</a>,<a href="#B33-ijms-24-09943" rid="B33-ijms-24-09943" class=" bibr popnode">33</a>,<a href="#B34-ijms-24-09943" rid="B34-ijms-24-09943" class=" bibr popnode">34</a>] represented by ETS Variant Transcription Factor 4 (ETV4), Sp1 Transcription Factor (SP1), CCAAT Enhancer Binding Protein Beta (CEBPB), TATA-Box Binding Protein (TBP), Forkhead Box A1 (FOXA1), Transcription Factor AP-2 Gamma (TFAP2C), X-Ray Repair Cross Complementing 6 (XRCC6), CCAAT Enhancer Binding Protein Alpha (CEBPA), X-Ray Repair Cross Complementing 5 (XRCC5), E74 Like ETS Transcription Factor 3 (ELF3), Transcription Factor AP-2 Beta (TFAP2A), YY1 Transcription Factor (YY1) and ETS Proto-Oncogene 1, Transcription Factor (ETS1), and a transcription activator (PHF8).</p><p class="p p-last">Pairwise correlation coefficients were determined for 240 gene combinations using the FPKM-UQ data for each gene. Correlation coefficients were visualized on a heatmap color coded for positive correlations (red = +1) to negative correlations (blue = &#x02212;1). The clustering algorithm identified co-regulated sets of mRNA expression values using the statistical package ggcorrplot_0.1.3 implemented in R software (R Foundation for Statistical Computing, Vienna, Austria). Significant correlations were identified for <em>t</em>-test <em>p</em>-values less than 0.05 and false discovery rates (FDRs) less than 0.05.</p></div><div id="sec4dot2-ijms-24-09943" class="sec"><h3 id="sec4dot2-ijms-24-09943title">4.2. Analysis of Patient Outcomes According to ERBB2/HER2 mRNA Expression Levels</h3><p class="p p-first">RNAseq and overall survival (OS) data were available for 787 MM patients. Progression-free survival (PFS) information was available for 669 MM patients. The Kaplan&#x02013;Meier (KM) method was employed utilizing the software packages survival_3.2-13, survminer_0.4.9, and survMisc_0.5.5 operated in the R environment to compare the progression-free survival (PFS) (<em>n</em> = 669), overall survival (OS) (<em>n</em> = 787), and cancer-related mortality (CRM) (<em>n</em> = 716) outcomes of patient subsets, as previously described [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]. Log-rank <em>p</em>-values less than 0.05 were deemed significant. Graphical representations of the survival curves were visualized using graph-drawing packages implemented in the R programming environment: dplyr_1.0.7, ggplot2_3.3.5, and ggthemes_4.2.4. The percentiles of patients expressing ERBB2/HER2 were determined using the metric fragments per kilobase of transcript per million mapped reads (FPKM) calculation normalized to the upper quartile FPKM (FPKM-UQ) for the whole geneset in each sample. PFS, OS, and cancer-related mortality (CRM) curves were compared for patients expressing high levels of ERBB2 (top 50th percentile of FPKM-UQ values) versus low levels of ERBB2 (bottom 50th percentile of FPKM-UQ values). Univariate Cox regression analyses were also performed to evaluate the impact of high-level ERBB2 expression on PFS and OS outcomes, as previously described [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]. We also investigated cancer-related mortality of four groups of patients with combinations of expression levels of ERBB1 and ERBB2: patients expressing high levels of both ERBB1 and ERBB2 (ERBB1<sup>high</sup>/ERBB2<sup>high</sup>; top 50th percentile for both ERBB1 and ERBB2 mRNA expression); low levels of ERBB1 and ERBB2 (ERBB1<sup>low</sup>/ERBB2<sup>low</sup>; below the 50th percentile of the lowest observed expression levels for both ERBB1 and ERBB2); and crossed combinations of ERBB1 and ERBB2 mRNA expression levels (ERBB1<sup>low</sup>/ERBB2<sup>high</sup>, and ERBB1<sup>high</sup>/ERBB2<sup>low</sup>).</p><p class="p p-last">Multivariate analyses of the potential effect of the MMRF CoMMpass ERBB2/HER2 cohort groups on the PFS, OS, and cancer-related mortality outcomes were performed using the multivariate Cox proportional hazards model to adjust for other patient risk factors and staging criteria, as previously described [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]. Briefly, the model included (i) the mRNA expression level for ERBB2 as a linear co-variate or as a categorical variable comparing high versus low ERBB2 mRNA expression levels (50% cut-off for the range of FPKM-UQ values), (ii) the prognostic staging data according to the International Staging System (ISS), (iii) age, (iv) serum concentrations for albumin concentration and beta 2 microglobulin level, implemented in R (survival_3.2-13 ran in R version 4.1.2. Forest Plots were utilized, as previously reported [<a href="#B25-ijms-24-09943" rid="B25-ijms-24-09943" class=" bibr popnode">25</a>]), to visualize the hazard ratios for Cox proportional hazards models for PFS, OS, and cancer-related mortality (survminer_0.4.9 ran in R version 4.1.2 (1 November 2021)). The life table hazard ratios (HRs) were estimated using the exponentiated regression coefficient for Cox proportional hazards analyses implemented in R (survival_3.2-13 ran in R version 4.1.2.).</p></div><div id="sec4dot3-ijms-24-09943" class="sec sec-last"><h3 id="sec4dot3-ijms-24-09943title">4.3. Identifying Prognostically Relevant Signaling Proteins Networked to ERBB2 Expression Using the STRING Interaction Algorithm</h3><p class="p p-first">Putative protein&#x02013;protein interaction networks derived from mRNA levels with prognostic impact on the OS were constructed using the STRING11.5 algorithm (<a href="http://string-db.org/">http://string-db.org/</a>, accessed 20 May 2023) to identify candidate hub proteins connecting ERBB2 gene expression to potential networked interactions involving intracellular signaling molecules [<a href="#B71-ijms-24-09943" rid="B71-ijms-24-09943" class=" bibr popnode">71</a>]. In these diagrams, the nodes depicted protein identifiers, and the edges depicted associations between the proteins.</p><p>Networks were visualized by first seeding the inputs and then growing the networks to identify connecting hubs between the inputs. The edges indicated the confidence level for the association calculated from various lines of experimental evidence (experiments, databases, and co-expression). Interaction scores greater than 0.7 were considered to define associations between the proteins and indicated by the thickness of the connecting lines for scores of 0.7 and 0.9. In the first instance, ERBB2 was seeded with the genes whose mRNA expression level was equal to or greater than the 50th percentile resulting in worse overall survival outcomes in 787 MM patients, namely, SHC1, CBL, PTPN11, FYN, KRAS, HRAS, NRAS, and MAP2K1.</p><p class="p p-last">These genes served as inputs to identify additional interactants by interrogating the STRING database for associations with scores equal to or greater than 0.7, no more than 20 interactants in the first shell, and no more than 5 interactants in the second shell of networked proteins. This iterative process identified a full module of 16 genes including ERBB2 whose augmented expression was highly associated with poor OS outcomes (<em>p</em> &#x0003c; 0.05, FDR &#x0003c; 0.1). A Kaplan&#x02013;Meier overall survival analysis was performed to compare the top 50th percentile expression of each gene coding for the networked protein versus the bottom 50th percentile expression that resulted in 16 genes exhibiting worse survival outcomes (Log-rank <em>p</em>-values &#x0003c; 0.05, FDR = 0.06) at higher levels of expression in MM patients, namely: CBL, CRKL, EIF4EBP1, ERBB2, FGR, FKBP1A, FYN, HRAS, KRAS, MAP2K1, MTOR, NRAS, PTPN11, RALA, RPS6KB1, and SHC1. A Markov cluster (MCL) algorithm was applied to visualize subnetworks of highly connected nodes in the 16 genes coding for proteins shown to result in worse survival outcomes in MM patients. The granularity of visualizing the subnetworks is controlled via the Markov cluster inflation factor ranging from 1.1 to 10 where, in our analysis, we discerned 2 highly connected sub-networks by setting the value to 2.1 for the 16 genes examined.</p></div></div><div id="sec5-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="sec5-ijms-24-09943title">5. Conclusions</h2><p class="p p-first-last">In MM patients, ERBB2 was expressed at significantly higher levels than ERBB1 as well as ERBB3 across all three stages of the disease. Upregulated expression of ERBB2 mRNA in MM cells was correlated with amplified expression of mRNAs for transcription factors that recognize the ERBB2 gene promoter sites. Patients with higher levels of ERBB2 mRNA in their malignant plasma cells experienced significantly increased cancer mortality, shorter progression-free survival, and worse overall survival than other patients. The adverse impact of high ERBB2 expression on patient survival outcomes remained significant in multivariate Cox proportional hazards models that accounted for the effects of other prognostic factors.</p></div><div id="app1-ijms-24-09943" class="tsec sec"><h2 class="head no_bottom_margin" id="app1-ijms-24-09943title">Supplementary Materials</h2><!--/article/back/app-group/app/--><p>The supporting information can be downloaded at: <a href="https://www.mdpi.com/article/10.3390/ijms24129943/s1">https://www.mdpi.com/article/10.3390/ijms24129943/s1</a>.</p><div class="sec suppmat" id="ijms-24-09943-s001"><div class="sup-box half_rhythm" id="media-a.n.b.a.c.a"><a href="/pmc/articles/PMC10298070/bin/ijms-24-09943-s001.zip" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(914K, zip)</sup></div></div></div><div id="funding-group-a.l.b.r" class="tsec sec"><h2 class="head no_bottom_margin" id="funding-group-a.l.b.rtitle">Funding Statement</h2><p>This study received funding from Ares Pharmaceuticals. Authors F.M.U. and S.Q. participated in the analysis and decision to submit the manuscript for publication are affiliated with the funder Ares Pharmaceuticals.</p></div><div id="notes-a.n.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.ctitle">Author Contributions</h2><p>Designed the evaluations reported in this paper, directed the data compilation and analysis, and prepared the initial draft of the manuscript: F.M.U. Performed statistical and bioinformatic analyses: S.Q. Analyzed, validated data, and reviewed and revised the manuscript, and provided final approval for submission of the final version: F.M.U. and S.Q. All authors have read and agreed to the published version of the manuscript.</p></div><div id="notes-a.n.d" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.dtitle">Institutional Review Board Statement</h2><p>Not applicable.</p></div><div id="notes-a.n.e" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.etitle">Informed Consent Statement</h2><p>Not applicable.</p></div><div id="notes-a.n.f" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.ftitle">Data Availability Statement</h2><p>All data are presented in the manuscript. The publicly available archived databases that were used to generate the data are provided in <a href="#sec2-ijms-24-09943" rid="sec2-ijms-24-09943" class=" sec">Section 2</a>. Gene level RNAseq raw count data (STAR-aligned unstranded number of reads aligned per gene per sample) were downloaded from the archived MMRF CoMMpass dataset by connecting to the GDC portal (<a href="https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf">https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/foundation-medicine/multiple-myeloma-research-foundation-mmrf</a> (accessed on 24 September 2022)) using the Bioconductor package, GenomicDataCommons_1.18.0 (release date 11 August 2021 with full functionality as provided by TCGAbiolinks for accessing GDC data (<a href="https://bioconductor.org/packages/release/bioc/html/GenomicDataCommons.html">https://bioconductor.org/packages/release/bioc/html/GenomicDataCommons.html</a> (accessed on 20 September 2022)) implemented in R version 4.1.2 (1 November 2021). The mRNA expression data were deposited in files appended with &#x0201c;&#x02026;.rna_seq.augmented_star_gene_counts.tsv&#x0201d;. Clinical data for each MM patient were also acquired via functions provided in GenomicDataCommons_1.18.0 and the case IDs were matched with RNAseq unique identifiers utilizing the metadata (&#x0201c;metadata.cart.2022-09-04.json&#x0201d;) from the GDC portal converted into R data by running the utilities rjson_0.2.21 and stringr_1.4.0.</p></div><div id="notes-a.n.g" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.n.gtitle">Conflicts of Interest</h2><p>The author F.M.U. is employed by Ares Pharmaceuticals, and the author S.Q. serves as a consultant for Ares Pharmaceuticals. All authors declare no other competing interest.</p></div><div id="fn-group-a.n.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.n.atitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.n.a.a"><p class="p p-first-last"><strong>Disclaimer/Publisher&#x02019;s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></p></div></div><div id="ref-list-a.n.h" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.n.htitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1-ijms-24-09943">1. <span class="element-citation">Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. <span><span class="ref-journal">EMBO J. </span>2000;<span class="ref-vol">19</span>:3159–3167. doi: 10.1093/emboj/19.13.3159.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC313958/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10880430" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Femboj%2F19.13.3159" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J.&amp;title=The+ErbB+signaling+network:+Receptor+heterodimerization+in+development+and+cancer&amp;author=M.A.+Olayioye&amp;author=R.M.+Neve&amp;author=H.A.+Lane&amp;author=N.E.+Hynes&amp;volume=19&amp;publication_year=2000&amp;pages=3159-3167&amp;pmid=10880430&amp;doi=10.1093/emboj/19.13.3159&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2-ijms-24-09943">2. <span class="element-citation">Jones J.Y., Akita R.W., Sliwkowski M. Binding specificities and affinities of egf domains for ErbB receptors. <span><span class="ref-journal">FEBS Lett. </span>1999;<span class="ref-vol">447</span>:227–231. doi: 10.1016/S0014-5793(99)00283-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10214951" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0014-5793(99)00283-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+Lett.&amp;title=Binding+specificities+and+affinities+of+egf+domains+for+ErbB+receptors&amp;author=J.Y.+Jones&amp;author=R.W.+Akita&amp;author=M.+Sliwkowski&amp;volume=447&amp;publication_year=1999&amp;pages=227-231&amp;pmid=10214951&amp;doi=10.1016/S0014-5793(99)00283-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3-ijms-24-09943">3. <span class="element-citation">Hassan G., Seno M. ERBB Signaling Pathway in Cancer Stem Cells. <span><span class="ref-journal">Adv. Exp. Med. Biol. </span>2022;<span class="ref-vol">1393</span>:65–81. doi: 10.1007/978-3-031-12974-2_3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36587302" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2F978-3-031-12974-2_3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Adv.+Exp.+Med.+Biol.&amp;title=ERBB+Signaling+Pathway+in+Cancer+Stem+Cells&amp;author=G.+Hassan&amp;author=M.+Seno&amp;volume=1393&amp;publication_year=2022&amp;pages=65-81&amp;pmid=36587302&amp;doi=10.1007/978-3-031-12974-2_3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4-ijms-24-09943">4. <span class="element-citation">Arkhipov A., Shan Y., Kim E.T., O Dror R., E Shaw D. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. <span><span class="ref-journal">eLife. </span>2013;<span class="ref-vol">2</span>:e00708. doi: 10.7554/eLife.00708.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3713454/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23878723" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.7554%2FeLife.00708" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=Her2+activation+mechanism+reflects+evolutionary+preservation+of+asymmetric+ectodomain+dimers+in+the+human+EGFR+family&amp;author=A.+Arkhipov&amp;author=Y.+Shan&amp;author=E.T.+Kim&amp;author=R.+O+Dror&amp;author=D.+E+Shaw&amp;volume=2&amp;publication_year=2013&amp;pages=e00708&amp;pmid=23878723&amp;doi=10.7554/eLife.00708&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5-ijms-24-09943">5. <span class="element-citation">Wells A. EGF receptor. <span><span class="ref-journal">Int. J. Biochem. Cell Biol. </span>1999;<span class="ref-vol">31</span>:637–643. doi: 10.1016/S1357-2725(99)00015-1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10404636" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1357-2725(99)00015-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Biochem.+Cell+Biol.&amp;title=EGF+receptor&amp;author=A.+Wells&amp;volume=31&amp;publication_year=1999&amp;pages=637-643&amp;pmid=10404636&amp;doi=10.1016/S1357-2725(99)00015-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6-ijms-24-09943">6. <span class="element-citation">Sabbah D.A., Hajjo R., Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. <span><span class="ref-journal">Curr. Top. Med. Chem. </span>2020;<span class="ref-vol">20</span>:815–834. doi: 10.2174/1568026620666200303123102.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32124699" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F1568026620666200303123102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr.+Top.+Med.+Chem.&amp;title=Review+on+Epidermal+Growth+Factor+Receptor+(EGFR)+Structure,+Signaling+Pathways,+Interactions,+and+Recent+Updates+of+EGFR+Inhibitors&amp;author=D.A.+Sabbah&amp;author=R.+Hajjo&amp;author=K.+Sweidan&amp;volume=20&amp;publication_year=2020&amp;pages=815-834&amp;pmid=32124699&amp;doi=10.2174/1568026620666200303123102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7-ijms-24-09943">7. <span class="element-citation">Wang Z. ErbB Receptors and Cancer. <span><span class="ref-journal">Methods Mol. Biol. </span>2017;<span class="ref-vol">1652</span>:3–35. doi: 10.1007/978-1-4939-7219-7_1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28791631" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2F978-1-4939-7219-7_1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Methods+Mol.+Biol.&amp;title=ErbB+Receptors+and+Cancer&amp;author=Z.+Wang&amp;volume=1652&amp;publication_year=2017&amp;pages=3-35&amp;pmid=28791631&amp;doi=10.1007/978-1-4939-7219-7_1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8-ijms-24-09943">8. <span class="element-citation">Santos E.D.S., Nogueira K.A.B., Fernandes L.C.C., Martins J.R.P., Reis A.V.F., Neto J.D.B.V., J&#x000fa;nior I.J.D.S., Pessoa C., Petrilli R., Eloy J.O. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. <span><span class="ref-journal">Int. J. Pharm. </span>2021;<span class="ref-vol">592</span>:120082. doi: 10.1016/j.ijpharm.2020.120082.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33188892" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ijpharm.2020.120082" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Pharm.&amp;title=EGFR+targeting+for+cancer+therapy:+Pharmacology+and+immunoconjugates+with+drugs+and+nanoparticles&amp;author=E.D.S.+Santos&amp;author=K.A.B.+Nogueira&amp;author=L.C.C.+Fernandes&amp;author=J.R.P.+Martins&amp;author=A.V.F.+Reis&amp;volume=592&amp;publication_year=2021&amp;pages=120082&amp;pmid=33188892&amp;doi=10.1016/j.ijpharm.2020.120082&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9-ijms-24-09943">9. <span class="element-citation">Hynes N.E., Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. <span><span class="ref-journal">Nat. Rev. Cancer. </span>2005;<span class="ref-vol">5</span>:341–354. doi: 10.1038/nrc1609.</span> Erratum in: <em>Nat. Rev. Cancer</em>
<strong>2005</strong>, <em>5</em>, 580. [<a href="https://pubmed.ncbi.nlm.nih.gov/15864276" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc1609" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Cancer&amp;title=ERBB+receptors+and+cancer:+The+complexity+of+targeted+inhibitors&amp;author=N.E.+Hynes&amp;author=H.A.+Lane&amp;volume=5&amp;publication_year=2005&amp;pages=341-354&amp;pmid=15864276&amp;doi=10.1038/nrc1609&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10-ijms-24-09943">10. <span class="element-citation">Ho C., Laskin J. EGFR-directed therapies to treat non-small-cell lung cancer. <span><span class="ref-journal">Expert Opin. Investig. Drugs. </span>2009;<span class="ref-vol">18</span>:1133–1145. doi: 10.1517/13543780903066772.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19572809" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1517%2F13543780903066772" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin.+Investig.+Drugs&amp;title=EGFR-directed+therapies+to+treat+non-small-cell+lung+cancer&amp;author=C.+Ho&amp;author=J.+Laskin&amp;volume=18&amp;publication_year=2009&amp;pages=1133-1145&amp;doi=10.1517/13543780903066772&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11-ijms-24-09943">11. <span class="element-citation">Ciardiello F., Tortora G. EGFR Antagonists in Cancer Treatment. <span><span class="ref-journal">N. Engl. J. Med. </span>2008;<span class="ref-vol">358</span>:1160–1174. doi: 10.1056/NEJMra0707704.</span> Erratum in: <em>N. Engl. J. Med.</em>
<strong>2009</strong>, <em>360</em>, 1579. [<a href="https://pubmed.ncbi.nlm.nih.gov/18337605" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMra0707704" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N.+Engl.+J.+Med.&amp;title=EGFR+Antagonists+in+Cancer+Treatment&amp;author=F.+Ciardiello&amp;author=G.+Tortora&amp;volume=358&amp;publication_year=2008&amp;pages=1160-1174&amp;pmid=18337605&amp;doi=10.1056/NEJMra0707704&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12-ijms-24-09943">12. <span class="element-citation">Marquez-Medina D., Popat S. Afatinib: A second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. <span><span class="ref-journal">Futur. Oncol. </span>2015;<span class="ref-vol">11</span>:2525–2540. doi: 10.2217/fon.15.183.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26314834" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2217%2Ffon.15.183" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Futur.+Oncol.&amp;title=Afatinib:+A+second-generation+EGF+receptor+and+ErbB+tyrosine+kinase+inhibitor+for+the+treatment+of+advanced+non-small-cell+lung+cancer&amp;author=D.+Marquez-Medina&amp;author=S.+Popat&amp;volume=11&amp;publication_year=2015&amp;pages=2525-2540&amp;doi=10.2217/fon.15.183&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13-ijms-24-09943">13. <span class="element-citation">Singh D., Attri B.K., Gill R.K., Bariwal J. Review on EGFR Inhibitors: Critical Updates. <span><span class="ref-journal">Mini-Rev. Med. Chem. </span>2016;<span class="ref-vol">16</span>:1134–1166. doi: 10.2174/1389557516666160321114917.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26996617" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2174%2F1389557516666160321114917" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mini-Rev.+Med.+Chem.&amp;title=Review+on+EGFR+Inhibitors:+Critical+Updates&amp;author=D.+Singh&amp;author=B.K.+Attri&amp;author=R.K.+Gill&amp;author=J.+Bariwal&amp;volume=16&amp;publication_year=2016&amp;pages=1134-1166&amp;pmid=26996617&amp;doi=10.2174/1389557516666160321114917&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14-ijms-24-09943">14. <span class="element-citation">Cai W.-Q., Zeng L.-S., Wang L.-F., Wang Y.-Y., Cheng J.-T., Zhang Y., Han Z.-W., Zhou Y., Huang S.-L., Wang X.-W., et al. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. <span><span class="ref-journal">Front. Oncol. </span>2020;<span class="ref-vol">10</span>:1249. doi: 10.3389/fonc.2020.01249.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7393266/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32793499" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2020.01249" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=The+Latest+Battles+Between+EGFR+Monoclonal+Antibodies+and+Resistant+Tumor+Cells&amp;author=W.-Q.+Cai&amp;author=L.-S.+Zeng&amp;author=L.-F.+Wang&amp;author=Y.-Y.+Wang&amp;author=J.-T.+Cheng&amp;volume=10&amp;publication_year=2020&amp;pages=1249&amp;pmid=32793499&amp;doi=10.3389/fonc.2020.01249&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15-ijms-24-09943">15. <span class="element-citation">Kumagai S., Koyama S., Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. <span><span class="ref-journal">Nat. Rev. Cancer. </span>2021;<span class="ref-vol">21</span>:181–197. doi: 10.1038/s41568-020-00322-0.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33462501" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41568-020-00322-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Cancer&amp;title=Antitumour+immunity+regulated+by+aberrant+ERBB+family+signalling&amp;author=S.+Kumagai&amp;author=S.+Koyama&amp;author=H.+Nishikawa&amp;volume=21&amp;publication_year=2021&amp;pages=181-197&amp;pmid=33462501&amp;doi=10.1038/s41568-020-00322-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16-ijms-24-09943">16. <span class="element-citation">Zaiss D.M.W., van Loosdregt J., Gorlani A., Bekker C.P.J., Gr&#x000f6;ne A., Sibilia M., van Bergen en Henegouwen P.M.P., Roovers R.C., Coffer P.J., Sijts A.J.A.M. Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor. <span><span class="ref-journal">Immunity. </span>2013;<span class="ref-vol">38</span>:275–284. doi: 10.1016/j.immuni.2012.09.023.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3582723/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23333074" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2012.09.023" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Amphiregulin+Enhances+Regulatory+T+Cell-Suppressive+Function+via+the+Epidermal+Growth+Factor+Receptor&amp;author=D.M.W.+Zaiss&amp;author=J.+van+Loosdregt&amp;author=A.+Gorlani&amp;author=C.P.J.+Bekker&amp;author=A.+Gr&#x000f6;ne&amp;volume=38&amp;publication_year=2013&amp;pages=275-284&amp;pmid=23333074&amp;doi=10.1016/j.immuni.2012.09.023&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17-ijms-24-09943">17. <span class="element-citation">Minutti C.M., Drube S., Blair N., Schwartz C., McCrae J.C., McKenzie A.N., Kamradt T., Mokry M., Coffer P.J., Sibilia M., et al. Epidermal Growth Factor Receptor Expression Licenses Type-2 Helper T Cells to Function in a T Cell Receptor-Independent Fashion. <span><span class="ref-journal">Immunity. </span>2017;<span class="ref-vol">47</span>:710–722.e6. doi: 10.1016/j.immuni.2017.09.013.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5654729/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29045902" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2017.09.013" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Epidermal+Growth+Factor+Receptor+Expression+Licenses+Type-2+Helper+T+Cells+to+Function+in+a+T+Cell+Receptor-Independent+Fashion&amp;author=C.M.+Minutti&amp;author=S.+Drube&amp;author=N.+Blair&amp;author=C.+Schwartz&amp;author=J.C.+McCrae&amp;volume=47&amp;publication_year=2017&amp;pages=710-722.e6&amp;pmid=29045902&amp;doi=10.1016/j.immuni.2017.09.013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18-ijms-24-09943">18. <span class="element-citation">Zeboudj L., Ma&#x000ee;tre M., Guyonnet L., Laurans L., Joffre J., Lemarie J., Bourcier S., Nour-Eldine W., Gu&#x000e9;rin C., Friard J., et al. Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis. <span><span class="ref-journal">J. Am. Coll. Cardiol. </span>2018;<span class="ref-vol">71</span>:160–172. doi: 10.1016/j.jacc.2017.10.084.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29325640" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jacc.2017.10.084" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Am.+Coll.+Cardiol.&amp;title=Selective+EGF-Receptor+Inhibition+in+CD4++T+Cells+Induces+Anergy+and+Limits+Atherosclerosis&amp;author=L.+Zeboudj&amp;author=M.+Ma&#x000ee;tre&amp;author=L.+Guyonnet&amp;author=L.+Laurans&amp;author=J.+Joffre&amp;volume=71&amp;publication_year=2018&amp;pages=160-172&amp;pmid=29325640&amp;doi=10.1016/j.jacc.2017.10.084&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19-ijms-24-09943">19. <span class="element-citation">Wang L., Huang Z., Huang W., Chen X., Shan P., Zhong P., Khan Z., Wang J., Fang Q., Liang G., et al. Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress. <span><span class="ref-journal">Sci. Rep. </span>2017;<span class="ref-vol">8</span>:45917. doi: 10.1038/srep45917.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5379239/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28374780" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsrep45917" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+Rep.&amp;title=Inhibition+of+epidermal+growth+factor+receptor+attenuates+atherosclerosis+via+decreasing+inflammation+and+oxidative+stress&amp;author=L.+Wang&amp;author=Z.+Huang&amp;author=W.+Huang&amp;author=X.+Chen&amp;author=P.+Shan&amp;volume=8&amp;publication_year=2017&amp;pages=45917&amp;pmid=28374780&amp;doi=10.1038/srep45917&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20-ijms-24-09943">20. <span class="element-citation">Spengeman J.D., Green T.D., Bertrand F.E., McCubrey J.A. Activated EGFR Promotes the Survival of B-Lineage Acute Leukemia in the Absence of Stromal Cells. <span><span class="ref-journal">Cell Cycle. </span>2005;<span class="ref-vol">4</span>:483–487. doi: 10.4161/cc.4.3.1533.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15701973" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fcc.4.3.1533" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Cycle&amp;title=Activated+EGFR+Promotes+the+Survival+of+B-Lineage+Acute+Leukemia+in+the+Absence+of+Stromal+Cells&amp;author=J.D.+Spengeman&amp;author=T.D.+Green&amp;author=F.E.+Bertrand&amp;author=J.A.+McCubrey&amp;volume=4&amp;publication_year=2005&amp;pages=483-487&amp;pmid=15701973&amp;doi=10.4161/cc.4.3.1533&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21-ijms-24-09943">21. <span class="element-citation">Mahtouk K., Hose D., R&#x000e8;me T., De Vos J., Jourdan M., Moreaux J., Fiol G., Raab M., Jourdan E., Grau V., et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:3512–3524. doi: 10.1038/sj.onc.1208536.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2408676/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15735670" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1208536" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Expression+of+EGF-family+receptors+and+amphiregulin+in+multiple+myeloma.+Amphiregulin+is+a+growth+factor+for+myeloma+cells&amp;author=K.+Mahtouk&amp;author=D.+Hose&amp;author=T.+R&#x000e8;me&amp;author=J.+De+Vos&amp;author=M.+Jourdan&amp;volume=24&amp;publication_year=2005&amp;pages=3512-3524&amp;pmid=15735670&amp;doi=10.1038/sj.onc.1208536&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22-ijms-24-09943">22. <span class="element-citation">Luo H., Zhang D., Wang F., Wang Q., Wu Y., Gou M., Hu Y., Zhang W., Huang J., Gong Y., et al. ALCAM-EGFR interaction regulates myelomagenesis. <span><span class="ref-journal">Blood Adv. </span>2021;<span class="ref-vol">5</span>:5269–5282. doi: 10.1182/bloodadvances.2021004695.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9152994/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34592762" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fbloodadvances.2021004695" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood+Adv.&amp;title=ALCAM-EGFR+interaction+regulates+myelomagenesis&amp;author=H.+Luo&amp;author=D.+Zhang&amp;author=F.+Wang&amp;author=Q.+Wang&amp;author=Y.+Wu&amp;volume=5&amp;publication_year=2021&amp;pages=5269-5282&amp;pmid=34592762&amp;doi=10.1182/bloodadvances.2021004695&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23-ijms-24-09943">23. <span class="element-citation">Chen Y., Huang R., Ding J., Ji D., Song B., Yuan L., Chang H., Chen G. Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. <span><span class="ref-journal">Sci. Rep. </span>2015;<span class="ref-vol">5</span>:9925. doi: 10.1038/srep09925.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4403500/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25894462" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsrep09925" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+Rep.&amp;title=Multiple+myeloma+acquires+resistance+to+EGFR+inhibitor+via+induction+of+pentose+phosphate+pathway&amp;author=Y.+Chen&amp;author=R.+Huang&amp;author=J.+Ding&amp;author=D.+Ji&amp;author=B.+Song&amp;volume=5&amp;publication_year=2015&amp;pages=9925&amp;pmid=25894462&amp;doi=10.1038/srep09925&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24-ijms-24-09943">24. <span class="element-citation">Raimondo S., Saieva L., Vicario E., Pucci M., Toscani D., Manno M., Raccosta S., Giuliani N., Alessandro R. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. <span><span class="ref-journal">J. Hematol. Oncol. </span>2019;<span class="ref-vol">12</span>:2. doi: 10.1186/s13045-018-0689-y.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6325886/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30621731" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13045-018-0689-y" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Hematol.+Oncol.&amp;title=Multiple+myeloma-derived+exosomes+are+enriched+of+amphiregulin+(AREG)+and+activate+the+epidermal+growth+factor+pathway+in+the+bone+microenvironment+leading+to+osteoclastogenesis&amp;author=S.+Raimondo&amp;author=L.+Saieva&amp;author=E.+Vicario&amp;author=M.+Pucci&amp;author=D.+Toscani&amp;volume=12&amp;publication_year=2019&amp;pages=2&amp;pmid=30621731&amp;doi=10.1186/s13045-018-0689-y&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25-ijms-24-09943">25. <span class="element-citation">Uckun F.M., Qazi S. ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. <span><span class="ref-journal">Onco. </span>2022;<span class="ref-vol">2</span>:282–304. doi: 10.3390/onco2040016.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9610889/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36311273" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fonco2040016" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Onco&amp;title=ERBB1/EGFR+and+JAK3+Tyrosine+Kinases+as+Potential+Therapeutic+Targets+in+High-Risk+Multiple+Myeloma&amp;author=F.M.+Uckun&amp;author=S.+Qazi&amp;volume=2&amp;publication_year=2022&amp;pages=282-304&amp;pmid=36311273&amp;doi=10.3390/onco2040016&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26-ijms-24-09943">26. <span class="element-citation">Fortschegger K., de Graaf P., Outchkourov N.S., van Schaik F.M.A., Timmers H.T.M., Shiekhattar R. PHF8 Targets Histone Methylation and RNA Polymerase II To Activate Transcription. <span><span class="ref-journal">Mol. Cell. Biol. </span>2010;<span class="ref-vol">30</span>:3286–3298. doi: 10.1128/MCB.01520-09.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2897584/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20421419" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1128%2FMCB.01520-09" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol.+Cell.+Biol.&amp;title=PHF8+Targets+Histone+Methylation+and+RNA+Polymerase+II+To+Activate+Transcription&amp;author=K.+Fortschegger&amp;author=P.+de+Graaf&amp;author=N.S.+Outchkourov&amp;author=F.M.A.+van+Schaik&amp;author=H.T.M.+Timmers&amp;volume=30&amp;publication_year=2010&amp;pages=3286-3298&amp;pmid=20421419&amp;doi=10.1128/MCB.01520-09&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27-ijms-24-09943">27. <span class="element-citation">Cruz R.G.B., Madden S.F., Brennan K., Hopkins A.M. A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer. <span><span class="ref-journal">Cells. </span>2022;<span class="ref-vol">11</span>:735.  doi: 10.3390/cells11040735.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8870165/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35203384" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcells11040735" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=A+Transcriptional+Link+between+HER2,+JAM-A+and+FOXA1+in+Breast+Cancer&amp;author=R.G.B.+Cruz&amp;author=S.F.+Madden&amp;author=K.+Brennan&amp;author=A.M.+Hopkins&amp;volume=11&amp;publication_year=2022&amp;pages=735&amp;pmid=35203384&amp;doi=10.3390/cells11040735&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28-ijms-24-09943">28. <span class="element-citation">Hasleton M., Ibbitt J.C., Hurst H.C. Characterization of the human activator protein-2gamma (AP-2gamma) gene: Control of expression by Sp1/Sp3 in breast tumour cells. Pt 3<span><span class="ref-journal">Biochem. J. </span>2003;<span class="ref-vol">373</span>:925–932. doi: 10.1042/bj20030388.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1223543/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12733991" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1042%2Fbj20030388" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.+J.&amp;title=Characterization+of+the+human+activator+protein-2gamma+(AP-2gamma)+gene:+Control+of+expression+by+Sp1/Sp3+in+breast+tumour+cells&amp;author=M.+Hasleton&amp;author=J.C.+Ibbitt&amp;author=H.C.+Hurst&amp;volume=373&amp;publication_year=2003&amp;pages=925-932&amp;pmid=12733991&amp;doi=10.1042/bj20030388&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29-ijms-24-09943">29. <span class="element-citation">Liu Q., Borcherding N.C., Shao P., Maina P.K., Zhang W., Qi H.H. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance. <span><span class="ref-journal">Ebiomedicine. </span>2020;<span class="ref-vol">51</span>:102612. doi: 10.1016/j.ebiom.2019.102612.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7000350/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31923801" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ebiom.2019.102612" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ebiomedicine&amp;title=Contribution+of+synergism+between+PHF8+and+HER2+signalling+to+breast+cancer+development+and+drug+resistance&amp;author=Q.+Liu&amp;author=N.C.+Borcherding&amp;author=P.+Shao&amp;author=P.K.+Maina&amp;author=W.+Zhang&amp;volume=51&amp;publication_year=2020&amp;pages=102612&amp;pmid=31923801&amp;doi=10.1016/j.ebiom.2019.102612&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30-ijms-24-09943">30. <span class="element-citation">Vernimmen U., Begon D., Salvador C., Gofflot S., Grooteclaes M., Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Pt 1<span><span class="ref-journal">Biochem. J. </span>2003;<span class="ref-vol">370</span>:323–329. doi: 10.1042/bj20021238.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1223148/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12418962" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1042%2Fbj20021238" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.+J.&amp;title=Identification+of+HTF+(HER2+transcription+factor)+as+an+AP-2+(activator+protein-2)+transcription+factor+and+contribution+of+the+HTF+binding+site+to+ERBB2+gene+overexpression&amp;author=U.+Vernimmen&amp;author=D.+Begon&amp;author=C.+Salvador&amp;author=S.+Gofflot&amp;author=M.+Grooteclaes&amp;volume=370&amp;publication_year=2003&amp;pages=323-329&amp;pmid=12418962&amp;doi=10.1042/bj20021238&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31-ijms-24-09943">31. <span class="element-citation">Nolens G., Pignon J.-C., Koopmansch B., Elmoualij B., Zorzi W., De Pauw E., Winkler R. Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2overexpression in breast cancer cell lines. <span><span class="ref-journal">Breast Cancer Res. </span>2009;<span class="ref-vol">11</span>:R83. doi: 10.1186/bcr2450.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2815545/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19906305" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fbcr2450" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res.&amp;title=Ku+proteins+interact+with+activator+protein-2+transcription+factors+and+contribute+to+ERBB2overexpression+in+breast+cancer+cell+lines&amp;author=G.+Nolens&amp;author=J.-C.+Pignon&amp;author=B.+Koopmansch&amp;author=B.+Elmoualij&amp;author=W.+Zorzi&amp;volume=11&amp;publication_year=2009&amp;pages=R83&amp;pmid=19906305&amp;doi=10.1186/bcr2450&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32-ijms-24-09943">32. <span class="element-citation">Begon D.Y., Delacroix L., Vernimmen D., Jackers P., Winkler R. Yin Yang 1 Cooperates with Activator Protein 2 to Stimulate ERBB2 Gene Expression in Mammary Cancer Cells. <span><span class="ref-journal">J. Biol. Chem. </span>2005;<span class="ref-vol">280</span>:24428–24434. doi: 10.1074/jbc.M503790200.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15870067" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.M503790200" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Biol.+Chem.&amp;title=Yin+Yang+1+Cooperates+with+Activator+Protein+2+to+Stimulate+ERBB2+Gene+Expression+in+Mammary+Cancer+Cells&amp;author=D.Y.+Begon&amp;author=L.+Delacroix&amp;author=D.+Vernimmen&amp;author=P.+Jackers&amp;author=R.+Winkler&amp;volume=280&amp;publication_year=2005&amp;pages=24428-24434&amp;pmid=15870067&amp;doi=10.1074/jbc.M503790200&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33-ijms-24-09943">33. <span class="element-citation">Hurst H.C. Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment. <span><span class="ref-journal">Breast Cancer Res. </span>2001;<span class="ref-vol">3</span>:395–398. doi: 10.1186/bcr329.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC138707/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11737892" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fbcr329" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Breast+Cancer+Res.&amp;title=Update+on+HER-2+as+a+target+for+cancer+therapy:+The+ERBB2+promoter+and+its+exploitation+for+cancer+treatment&amp;author=H.C.+Hurst&amp;volume=3&amp;publication_year=2001&amp;pages=395-398&amp;pmid=11737892&amp;doi=10.1186/bcr329&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34-ijms-24-09943">34. <span class="element-citation">Ishii S., Imamoto F., Yamanashi Y., Toyoshima K., Yamamoto T. Characterization of the promoter region of the human c-erbB-2 protooncogene. <span><span class="ref-journal">Proc. Natl. Acad. Sci. USA. </span>1987;<span class="ref-vol">84</span>:4374–4378. doi: 10.1073/pnas.84.13.4374.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC305091/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2885835" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.84.13.4374" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc.+Natl.+Acad.+Sci.+USA&amp;title=Characterization+of+the+promoter+region+of+the+human+c-erbB-2+protooncogene&amp;author=S.+Ishii&amp;author=F.+Imamoto&amp;author=Y.+Yamanashi&amp;author=K.+Toyoshima&amp;author=T.+Yamamoto&amp;volume=84&amp;publication_year=1987&amp;pages=4374-4378&amp;pmid=2885835&amp;doi=10.1073/pnas.84.13.4374&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35-ijms-24-09943">35. <span class="element-citation">Das S., Juliana N., Abu Yazit N.A., Azmani S., Abu I.F. Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment. <span><span class="ref-journal">Int. J. Mol. Sci. </span>2022;<span class="ref-vol">23</span>:1649.  doi: 10.3390/ijms23031649.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8836148/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35163567" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms23031649" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Mol.+Sci.&amp;title=Multiple+Myeloma:+Challenges+Encountered+and+Future+Options+for+Better+Treatment&amp;author=S.+Das&amp;author=N.+Juliana&amp;author=N.A.+Abu+Yazit&amp;author=S.+Azmani&amp;author=I.F.+Abu&amp;volume=23&amp;publication_year=2022&amp;pages=1649&amp;pmid=35163567&amp;doi=10.3390/ijms23031649&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36-ijms-24-09943">36. <span class="element-citation">Saldarriaga M.M., Darwiche W., Jayabalan D., Monge J., Rosenbaum C., Pearse R.N., Niesvizky R., Bustoros M. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. <span><span class="ref-journal">Front. Oncol. </span>2022;<span class="ref-vol">12</span>:1020011. doi: 10.3389/fonc.2022.1020011.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9646612/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36387095" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2022.1020011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Advances+in+the+molecular+characterization+of+multiple+myeloma+and+mechanism+of+therapeutic+resistance&amp;author=M.M.+Saldarriaga&amp;author=W.+Darwiche&amp;author=D.+Jayabalan&amp;author=J.+Monge&amp;author=C.+Rosenbaum&amp;volume=12&amp;publication_year=2022&amp;pages=1020011&amp;pmid=36387095&amp;doi=10.3389/fonc.2022.1020011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37-ijms-24-09943">37. <span class="element-citation">Uckun F.M., Qazi S., Demirer T., Champlin R.E. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. <span><span class="ref-journal">Ebiomedicine. </span>2018;<span class="ref-vol">39</span>:612–620. doi: 10.1016/j.ebiom.2018.12.004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6354702/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30545798" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ebiom.2018.12.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ebiomedicine&amp;title=Contemporary+patient-tailored+treatment+strategies+against+high+risk+and+relapsed+or+refractory+multiple+myeloma&amp;author=F.M.+Uckun&amp;author=S.+Qazi&amp;author=T.+Demirer&amp;author=R.E.+Champlin&amp;volume=39&amp;publication_year=2018&amp;pages=612-620&amp;pmid=30545798&amp;doi=10.1016/j.ebiom.2018.12.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38-ijms-24-09943">38. <span class="element-citation">Gulla&#x02019; A., Anderson K.C. Multiple myeloma: The (r)evolution of current therapy and a glance into future. <span><span class="ref-journal">Haematologica. </span>2020;<span class="ref-vol">105</span>:2358–2367. doi: 10.3324/haematol.2020.247015.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7556665/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33054076" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3324%2Fhaematol.2020.247015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Multiple+myeloma:+The+(r)evolution+of+current+therapy+and+a+glance+into+future&amp;author=A.+Gulla&#x02019;&amp;author=K.C.+Anderson&amp;volume=105&amp;publication_year=2020&amp;pages=2358-2367&amp;pmid=33054076&amp;doi=10.3324/haematol.2020.247015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39-ijms-24-09943">39. <span class="element-citation">Uckun F.M. Cancer drug resistance in multiple myeloma. <span><span class="ref-journal">Cancer Drug Resist. </span>2022;<span class="ref-vol">5</span>:271–276. doi: 10.20517/cdr.2022.32.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9255243/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35800374" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.20517%2Fcdr.2022.32" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Drug+Resist.&amp;title=Cancer+drug+resistance+in+multiple+myeloma&amp;author=F.M.+Uckun&amp;volume=5&amp;publication_year=2022&amp;pages=271-276&amp;pmid=35800374&amp;doi=10.20517/cdr.2022.32&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40-ijms-24-09943">40. <span class="element-citation">Moreau P., Kumar S.K., San Miguel J., Davies F., Zamagni E., Bahlis N., Ludwig H., Mikhael J., Terpos E., Schjesvold F., et al. Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group. <span><span class="ref-journal">Lancet Oncol. </span>2021;<span class="ref-vol">22</span>:e105–e118. doi: 10.1016/S1470-2045(20)30756-7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33662288" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS1470-2045(20)30756-7" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol.&amp;title=Treatment+of+relapsed+and+refractory+multiple+myeloma:+Recommendations+from+the+International+Myeloma+Working+Group&amp;author=P.+Moreau&amp;author=S.K.+Kumar&amp;author=J.+San+Miguel&amp;author=F.+Davies&amp;author=E.+Zamagni&amp;volume=22&amp;publication_year=2021&amp;pages=e105-e118&amp;pmid=33662288&amp;doi=10.1016/S1470-2045(20)30756-7&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41-ijms-24-09943">41. <span class="element-citation">Cavo M., Terpos E., Bargay J., Einsele H., Cavet J., Greil R. The multiple myeloma treatment landscape: International guide-line recommendations and clinical practice in Europe. <span><span class="ref-journal">Expert Rev. Hematol. </span>2018;<span class="ref-vol">11</span>:219–237. doi: 10.1080/17474086.2018.1437345.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29415570" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F17474086.2018.1437345" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev.+Hematol.&amp;title=The+multiple+myeloma+treatment+landscape:+International+guide-line+recommendations+and+clinical+practice+in+Europe&amp;author=M.+Cavo&amp;author=E.+Terpos&amp;author=J.+Bargay&amp;author=H.+Einsele&amp;author=J.+Cavet&amp;volume=11&amp;publication_year=2018&amp;pages=219-237&amp;pmid=29415570&amp;doi=10.1080/17474086.2018.1437345&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42-ijms-24-09943">42. <span class="element-citation">Swamydas M., Murphy E.V., Ignatz-Hoover J.J., Malek E., Driscoll J.J. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. <span><span class="ref-journal">J. Hematol. Oncol. </span>2022;<span class="ref-vol">15</span>:1–17. doi: 10.1186/s13045-022-01234-2.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8848665/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35172851" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13045-022-01234-2" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Hematol.+Oncol.&amp;title=Deciphering+mechanisms+of+immune+escape+to+inform+immunotherapeutic+strategies+in+multiple+myeloma&amp;author=M.+Swamydas&amp;author=E.V.+Murphy&amp;author=J.J.+Ignatz-Hoover&amp;author=E.+Malek&amp;author=J.J.+Driscoll&amp;volume=15&amp;publication_year=2022&amp;pages=1-17&amp;pmid=34991679&amp;doi=10.1186/s13045-022-01234-2&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43-ijms-24-09943">43. <span class="element-citation">Uckun F.M. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. <span><span class="ref-journal">Front. Oncol. </span>2021;<span class="ref-vol">11</span>:760382. doi: 10.3389/fonc.2021.760382.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8631522/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34858838" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2021.760382" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Dual+Targeting+of+Multiple+Myeloma+Stem+Cells+and+Myeloid-Derived+Suppressor+Cells+for+Treatment+of+Chemotherapy-Resistant+Multiple+Myeloma&amp;author=F.M.+Uckun&amp;volume=11&amp;publication_year=2021&amp;pages=760382&amp;pmid=34858838&amp;doi=10.3389/fonc.2021.760382&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44-ijms-24-09943">44. <span class="element-citation">Lomas O.C., Tahri S., Ghobrial I.M. The microenvironment in myeloma. <span><span class="ref-journal">Curr. Opin. Oncol. </span>2020;<span class="ref-vol">32</span>:170–175. doi: 10.1097/CCO.0000000000000615.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31895122" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1097%2FCCO.0000000000000615" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr.+Opin.+Oncol.&amp;title=The+microenvironment+in+myeloma&amp;author=O.C.+Lomas&amp;author=S.+Tahri&amp;author=I.M.+Ghobrial&amp;volume=32&amp;publication_year=2020&amp;pages=170-175&amp;pmid=31895122&amp;doi=10.1097/CCO.0000000000000615&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45-ijms-24-09943">45. <span class="element-citation">Forster S., Radpour R. Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease. <span><span class="ref-journal">Front. Oncol. </span>2022;<span class="ref-vol">12</span>:941437. doi: 10.3389/fonc.2022.941437.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9284036/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35847862" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2022.941437" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Molecular+Impact+of+the+Tumor+Microenvironment+on+Multiple+Myeloma+Dissemination+and+Extramedullary+Disease&amp;author=S.+Forster&amp;author=R.+Radpour&amp;volume=12&amp;publication_year=2022&amp;pages=941437&amp;pmid=35847862&amp;doi=10.3389/fonc.2022.941437&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46-ijms-24-09943">46. <span class="element-citation">Neumeister P., Schulz E., Pansy K., Szmyra M., Deutsch A.J. Targeting the Microenvironment for Treating Multiple Myeloma. <span><span class="ref-journal">Int. J. Mol. Sci. </span>2022;<span class="ref-vol">23</span>:7627.  doi: 10.3390/ijms23147627.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9317002/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35886976" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms23147627" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Mol.+Sci.&amp;title=Targeting+the+Microenvironment+for+Treating+Multiple+Myeloma&amp;author=P.+Neumeister&amp;author=E.+Schulz&amp;author=K.+Pansy&amp;author=M.+Szmyra&amp;author=A.J.+Deutsch&amp;volume=23&amp;publication_year=2022&amp;pages=7627&amp;pmid=35886976&amp;doi=10.3390/ijms23147627&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47-ijms-24-09943">47. <span class="element-citation">Garc&#x000ed;a-Ortiz A., Rodr&#x000ed;guez-Garc&#x000ed;a Y., Encinas J., Maroto-Mart&#x000ed;n E., Castellano E., Teixid&#x000f3; J., Mart&#x000ed;nez-L&#x000f3;pez J. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. <span><span class="ref-journal">Cancers. </span>2021;<span class="ref-vol">13</span>:217.  doi: 10.3390/cancers13020217.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7827690/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33435306" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers13020217" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=The+Role+of+Tumor+Microenvironment+in+Multiple+Myeloma+Development+and+Progression&amp;author=A.+Garc&#x000ed;a-Ortiz&amp;author=Y.+Rodr&#x000ed;guez-Garc&#x000ed;a&amp;author=J.+Encinas&amp;author=E.+Maroto-Mart&#x000ed;n&amp;author=E.+Castellano&amp;volume=13&amp;publication_year=2021&amp;pages=217&amp;pmid=33435306&amp;doi=10.3390/cancers13020217&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48-ijms-24-09943">48. <span class="element-citation">Giannotta C., Autino F., Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells. <span><span class="ref-journal">Front. Immunol. </span>2023;<span class="ref-vol">13</span>:1102471. doi: 10.3389/fimmu.2022.1102471.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9885853/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36726975" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffimmu.2022.1102471" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Immunol.&amp;title=The+immune+suppressive+tumor+microenvironment+in+multiple+myeloma:+The+contribution+of+myeloid-derived+suppressor+cells&amp;author=C.+Giannotta&amp;author=F.+Autino&amp;author=M.+Massaia&amp;volume=13&amp;publication_year=2023&amp;pages=1102471&amp;pmid=36726975&amp;doi=10.3389/fimmu.2022.1102471&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49-ijms-24-09943">49. <span class="element-citation">Uckun F.M. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. <span><span class="ref-journal">Cancers. </span>2021;<span class="ref-vol">13</span>:2018.  doi: 10.3390/cancers13092018.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8122391/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33922005" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers13092018" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Overcoming+the+Immunosuppressive+Tumor+Microenvironment+in+Multiple+Myeloma&amp;author=F.M.+Uckun&amp;volume=13&amp;publication_year=2021&amp;pages=2018&amp;pmid=33922005&amp;doi=10.3390/cancers13092018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50-ijms-24-09943">50. <span class="element-citation">Shin S.Y., Lee D.H., Lee J., Choi C., Kim J.-Y., Nam J.-S., Lim Y., Lee Y.H. C-C motif chemokine receptor 1 (CCR1) is a target of the EGF-AKT-mTOR-STAT3 signaling axis in breast cancer cells. <span><span class="ref-journal">Oncotarget. </span>2017;<span class="ref-vol">8</span>:94591–94605. doi: 10.18632/oncotarget.21813.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5706898/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29212252" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.21813" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=C-C+motif+chemokine+receptor+1+(CCR1)+is+a+target+of+the+EGF-AKT-mTOR-STAT3+signaling+axis+in+breast+cancer+cells&amp;author=S.Y.+Shin&amp;author=D.H.+Lee&amp;author=J.+Lee&amp;author=C.+Choi&amp;author=J.-Y.+Kim&amp;volume=8&amp;publication_year=2017&amp;pages=94591-94605&amp;pmid=29212252&amp;doi=10.18632/oncotarget.21813&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51-ijms-24-09943">51. <span class="element-citation">Kara I.O., Sahin B., G&#x000fc;nesacar R., Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-&#x003b1; in bone marrow and peripheral blood of patients with multiple myeloma. <span><span class="ref-journal">Adv. Ther. </span>2006;<span class="ref-vol">23</span>:635–645. doi: 10.1007/BF02850052.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17050506" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2FBF02850052" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Adv.+Ther.&amp;title=Clinical+significance+of+hepatocyte+growth+factor,+platelet-derived+growth+factor-AB,+and+transforming+growth+factor-&#x003b1;+in+bone+marrow+and+peripheral+blood+of+patients+with+multiple+myeloma&amp;author=I.O.+Kara&amp;author=B.+Sahin&amp;author=R.+G&#x000fc;nesacar&amp;author=C.+Unsal&amp;volume=23&amp;publication_year=2006&amp;pages=635-645&amp;pmid=17050506&amp;doi=10.1007/BF02850052&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52-ijms-24-09943">52. <span class="element-citation">Musolino C., Allegra A., Innao V., Allegra A.G., Pioggia G., Gangemi S. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. <span><span class="ref-journal">Mediat. Inflamm. </span>2017;<span class="ref-vol">2017</span>:1–24. doi: 10.1155/2017/1852517.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5635476/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29089667" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1155%2F2017%2F1852517" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mediat.+Inflamm.&amp;title=Inflammatory+and+Anti-Inflammatory+Equilibrium,+Proliferative+and+Antiproliferative+Balance:+The+Role+of+Cytokines+in+Multiple+Myeloma&amp;author=C.+Musolino&amp;author=A.+Allegra&amp;author=V.+Innao&amp;author=A.G.+Allegra&amp;author=G.+Pioggia&amp;volume=2017&amp;publication_year=2017&amp;pages=1-24&amp;doi=10.1155/2017/1852517&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53-ijms-24-09943">53. <span class="element-citation">Akhtar S., Ali T.A., Faiyaz A., Khan O.S., Raza S.S., Kulinski M., El Omri H., Bhat A.A., Uddin S. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma. <span><span class="ref-journal">Int. J. Mol. Sci. </span>2020;<span class="ref-vol">21</span>:5002.  doi: 10.3390/ijms21145002.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7403981/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32679860" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fijms21145002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Mol.+Sci.&amp;title=Cytokine-Mediated+Dysregulation+of+Signaling+Pathways+in+the+Pathogenesis+of+Multiple+Myeloma&amp;author=S.+Akhtar&amp;author=T.A.+Ali&amp;author=A.+Faiyaz&amp;author=O.S.+Khan&amp;author=S.S.+Raza&amp;volume=21&amp;publication_year=2020&amp;pages=5002&amp;pmid=32679860&amp;doi=10.3390/ijms21145002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54-ijms-24-09943">54. <span class="element-citation">Melaccio A., Reale A., Saltarella I., Desantis V., Lamanuzzi A., Cicco S., Frassanito M.A., Vacca A., Ria R. Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance. <span><span class="ref-journal">J. Clin. Med. </span>2022;<span class="ref-vol">11</span>:6491.  doi: 10.3390/jcm11216491.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9658666/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36362718" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fjcm11216491" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Clin.+Med.&amp;title=Pathways+of+Angiogenic+and+Inflammatory+Cytokines+in+Multiple+Myeloma:+Role+in+Plasma+Cell+Clonal+Expansion+and+Drug+Resistance&amp;author=A.+Melaccio&amp;author=A.+Reale&amp;author=I.+Saltarella&amp;author=V.+Desantis&amp;author=A.+Lamanuzzi&amp;volume=11&amp;publication_year=2022&amp;pages=6491&amp;pmid=36362718&amp;doi=10.3390/jcm11216491&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55-ijms-24-09943">55. <span class="element-citation">Matsumoto M., Baba A., Yokota T., Nishikawa H., Ohkawa Y., Kayama H., Kallies A., Nutt S.L., Sakaguchi S., Takeda K., et al. Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation. <span><span class="ref-journal">Immunity. </span>2014;<span class="ref-vol">41</span>:1040–1051. doi: 10.1016/j.immuni.2014.10.016.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25484301" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.immuni.2014.10.016" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Interleukin-10-Producing+Plasmablasts+Exert+Regulatory+Function+in+Autoimmune+Inflammation&amp;author=M.+Matsumoto&amp;author=A.+Baba&amp;author=T.+Yokota&amp;author=H.+Nishikawa&amp;author=Y.+Ohkawa&amp;volume=41&amp;publication_year=2014&amp;pages=1040-1051&amp;pmid=25484301&amp;doi=10.1016/j.immuni.2014.10.016&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56-ijms-24-09943">56. <span class="element-citation">Takagi S., Tsukamoto S., Park J., Johnson K.E., Kawano Y., Moschetta M., Liu C.-J., Mishima Y., Kokubun K., Manier S., et al. Platelets Enhance Multiple Myeloma Progression via IL-1&#x003b2; Upregulation. <span><span class="ref-journal">Clin. Cancer Res. </span>2018;<span class="ref-vol">24</span>:2430–2439. doi: 10.1158/1078-0432.CCR-17-2003.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29440174" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-17-2003" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Cancer+Res.&amp;title=Platelets+Enhance+Multiple+Myeloma+Progression+via+IL-1&#x003b2;+Upregulation&amp;author=S.+Takagi&amp;author=S.+Tsukamoto&amp;author=J.+Park&amp;author=K.E.+Johnson&amp;author=Y.+Kawano&amp;volume=24&amp;publication_year=2018&amp;pages=2430-2439&amp;pmid=29440174&amp;doi=10.1158/1078-0432.CCR-17-2003&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57-ijms-24-09943">57. <span class="element-citation">Narayan P., Osgood C.L., Singh H., Chiu H.-J., Ricks T.K., Chow E.C.Y., Qiu J., Song P., Yu J., Namuswe F., et al. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. <span><span class="ref-journal">Clin. Cancer Res. </span>2021;<span class="ref-vol">27</span>:4478–4485. doi: 10.1158/1078-0432.CCR-20-4557.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8570919/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33753456" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-20-4557" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Cancer+Res.&amp;title=FDA+Approval+Summary:+Fam-Trastuzumab+Deruxtecan-Nxki+for+the+Treatment+of+Unresectable+or+Metastatic+HER2-Positive+Breast+Cancer&amp;author=P.+Narayan&amp;author=C.L.+Osgood&amp;author=H.+Singh&amp;author=H.-J.+Chiu&amp;author=T.K.+Ricks&amp;volume=27&amp;publication_year=2021&amp;pages=4478-4485&amp;pmid=33753456&amp;doi=10.1158/1078-0432.CCR-20-4557&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58-ijms-24-09943">58. <span class="element-citation">Kunte S., Abraham J., Montero A.J. Novel HER2&#x02013;targeted therapies for HER2&#x02013;positive metastatic breast cancer. <span><span class="ref-journal">Cancer. </span>2020;<span class="ref-vol">126</span>:4278–4288. doi: 10.1002/cncr.33102.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32721042" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fcncr.33102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Novel+HER2&#x02013;targeted+therapies+for+HER2&#x02013;positive+metastatic+breast+cancer&amp;author=S.+Kunte&amp;author=J.+Abraham&amp;author=A.J.+Montero&amp;volume=126&amp;publication_year=2020&amp;pages=4278-4288&amp;pmid=32721042&amp;doi=10.1002/cncr.33102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59-ijms-24-09943">59. <span class="element-citation">Gupta R., Gupta S., Antonios B., Ghimire B., Jindal V., Deol J., Gaikazian S., Huben M., Anderson J., Stender M., et al. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. <span><span class="ref-journal">Med. Oncol. </span>2022;<span class="ref-vol">39</span>:1–14. doi: 10.1007/s12032-022-01849-y.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36224475" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs12032-022-01849-y" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Med.+Oncol.&amp;title=Therapeutic+landscape+of+advanced+HER2-positive+breast+cancer+in+2022&amp;author=R.+Gupta&amp;author=S.+Gupta&amp;author=B.+Antonios&amp;author=B.+Ghimire&amp;author=V.+Jindal&amp;volume=39&amp;publication_year=2022&amp;pages=1-14&amp;doi=10.1007/s12032-022-01849-y&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60-ijms-24-09943">60. <span class="element-citation">Hideshima T., Anderson K.C. Signaling Pathway Mediating Myeloma Cell Growth and Survival. <span><span class="ref-journal">Cancers. </span>2021;<span class="ref-vol">13</span>:216.  doi: 10.3390/cancers13020216.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7827005/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33435632" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers13020216" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Signaling+Pathway+Mediating+Myeloma+Cell+Growth+and+Survival&amp;author=T.+Hideshima&amp;author=K.C.+Anderson&amp;volume=13&amp;publication_year=2021&amp;pages=216&amp;pmid=33435632&amp;doi=10.3390/cancers13020216&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61-ijms-24-09943">61. <span class="element-citation">Zhou J., Chng W.-J. Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma. <span><span class="ref-journal">Cells. </span>2022;<span class="ref-vol">11</span>:941.  doi: 10.3390/cells11060941.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8946161/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35326392" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcells11060941" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Biological+Hallmarks+and+Emerging+Strategies+to+Target+STAT3+Signaling+in+Multiple+Myeloma&amp;author=J.+Zhou&amp;author=W.-J.+Chng&amp;volume=11&amp;publication_year=2022&amp;pages=941&amp;pmid=35326392&amp;doi=10.3390/cells11060941&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B62-ijms-24-09943">62. <span class="element-citation">Rana P.S., Soler D.C., Kort J., Driscoll J.J. Targeting TGF-&#x003b2; signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction. <span><span class="ref-journal">Front. Cell Dev. Biol. </span>2022;<span class="ref-vol">10</span>:1059715. doi: 10.3389/fcell.2022.1059715.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9790996/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36578789" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffcell.2022.1059715" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Cell+Dev.+Biol.&amp;title=Targeting+TGF-&#x003b2;+signaling+in+the+multiple+myeloma+microenvironment:+Steering+CARs+and+T+cells+in+the+right+direction&amp;author=P.S.+Rana&amp;author=D.C.+Soler&amp;author=J.+Kort&amp;author=J.J.+Driscoll&amp;volume=10&amp;publication_year=2022&amp;pages=1059715&amp;pmid=36578789&amp;doi=10.3389/fcell.2022.1059715&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B63-ijms-24-09943">63. <span class="element-citation">Gilchrist A., Echeverria S.L. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma. <span><span class="ref-journal">Front. Endocrinol. </span>2022;<span class="ref-vol">13</span>:846310. doi: 10.3389/fendo.2022.846310.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8991687/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35399952" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffendo.2022.846310" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Endocrinol.&amp;title=Targeting+Chemokine+Receptor+CCR1+as+a+Potential+Therapeutic+Approach+for+Multiple+Myeloma&amp;author=A.+Gilchrist&amp;author=S.L.+Echeverria&amp;volume=13&amp;publication_year=2022&amp;pages=846310&amp;pmid=35399952&amp;doi=10.3389/fendo.2022.846310&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B64-ijms-24-09943">64. <span class="element-citation">Minakata D., Fujiwara S., Yokoyama D., Noguchi A., Aoe S., Oyama T., Koyama S., Murahashi R., Nakashima H., Hyodo K., et al. Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. <span class="ref-journal">Br. J. Haematol.</span> 2023.  
<em>ahead of print</em>
. [<a href="https://pubmed.ncbi.nlm.nih.gov/36661264" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fbjh.18654" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>]</span></div><div class="ref-cit-blk half_rhythm" id="B65-ijms-24-09943">65. <span class="element-citation">Coira I.F., Rinc&#x000f3;n R., Cuendet M. The Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAs. <span><span class="ref-journal">Cancers. </span>2022;<span class="ref-vol">14</span>:2348.  doi: 10.3390/cancers14102348.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9139326/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35625953" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers14102348" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=The+Multiple+Myeloma+Landscape:+Epigenetics+and+Non-Coding+RNAs&amp;author=I.F.+Coira&amp;author=R.+Rinc&#x000f3;n&amp;author=M.+Cuendet&amp;volume=14&amp;publication_year=2022&amp;pages=2348&amp;pmid=35625953&amp;doi=10.3390/cancers14102348&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B66-ijms-24-09943">66. <span class="element-citation">Barreto I.V., Machado C.B., Almeida D.B., Pessoa F.M.C.D.P., Gadelha R.B., Pantoja L.D.C., Oliveira D.D.S., Ribeiro R.M., Lopes G.S., Filho M.O.D.M., et al. Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. <span><span class="ref-journal">Pharmaceutics. </span>2022;<span class="ref-vol">14</span>:1784.  doi: 10.3390/pharmaceutics14091784.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9506264/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36145532" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fpharmaceutics14091784" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=Kinase+Inhibition+in+Multiple+Myeloma:+Current+Scenario+and+Clinical+Perspectives&amp;author=I.V.+Barreto&amp;author=C.B.+Machado&amp;author=D.B.+Almeida&amp;author=F.M.C.D.P.+Pessoa&amp;author=R.B.+Gadelha&amp;volume=14&amp;publication_year=2022&amp;pages=1784&amp;pmid=36145532&amp;doi=10.3390/pharmaceutics14091784&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B67-ijms-24-09943">67. <span class="element-citation">Solimando A.G., Malerba E., Leone P., Prete M., Terragna C., Cavo M., Racanelli V. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. <span><span class="ref-journal">Front. Oncol. </span>2022;<span class="ref-vol">12</span>:973836. doi: 10.3389/fonc.2022.973836.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9533079/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36212502" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2022.973836" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Drug+resistance+in+multiple+myeloma:+Soldiers+and+weapons+in+the+bone+marrow+niche&amp;author=A.G.+Solimando&amp;author=E.+Malerba&amp;author=P.+Leone&amp;author=M.+Prete&amp;author=C.+Terragna&amp;volume=12&amp;publication_year=2022&amp;pages=973836&amp;pmid=36212502&amp;doi=10.3389/fonc.2022.973836&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B68-ijms-24-09943">68. <span class="element-citation">Yamamoto L., Amodio N., Gulla A., Anderson K.C. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. <span><span class="ref-journal">Front. Oncol. </span>2021;<span class="ref-vol">10</span>:6368. doi: 10.3389/fonc.2020.606368.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7873734/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33585226" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2020.606368" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Harnessing+the+Immune+System+Against+Multiple+Myeloma:+Challenges+and+Opportunities&amp;author=L.+Yamamoto&amp;author=N.+Amodio&amp;author=A.+Gulla&amp;author=K.C.+Anderson&amp;volume=10&amp;publication_year=2021&amp;pages=6368&amp;doi=10.3389/fonc.2020.606368&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B69-ijms-24-09943">69. <span class="element-citation">Minnie S.A., Hill G.R. Immunotherapy of multiple myeloma. <span><span class="ref-journal">J. Clin. Investig. </span>2020;<span class="ref-vol">130</span>:1565–1575. doi: 10.1172/JCI129205.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7108923/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32149732" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2FJCI129205" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Clin.+Investig.&amp;title=Immunotherapy+of+multiple+myeloma&amp;author=S.A.+Minnie&amp;author=G.R.+Hill&amp;volume=130&amp;publication_year=2020&amp;pages=1565-1575&amp;pmid=32149732&amp;doi=10.1172/JCI129205&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B70-ijms-24-09943">70. <span class="element-citation">Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <span><span class="ref-journal">Genome Biol. </span>2014;<span class="ref-vol">15</span>:550. doi: 10.1186/s13059-014-0550-8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4302049/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25516281" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13059-014-0550-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genome+Biol.&amp;title=Moderated+estimation+of+fold+change+and+dispersion+for+RNA-seq+data+with+DESeq2&amp;author=M.I.+Love&amp;author=W.+Huber&amp;author=S.+Anders&amp;volume=15&amp;publication_year=2014&amp;pages=550&amp;pmid=25516281&amp;doi=10.1186/s13059-014-0550-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B71-ijms-24-09943">71. <span class="element-citation">Von Mering C., Jensen L.J., Snel B., Hooper S.D., Krupp M., Foglierini M., Jouffre N., Huynen M.A., Bork P. STRING: Known and predicted protein-protein associations, integrated and transferred across organisms. <span><span class="ref-journal">Nucleic Acids Res. </span>2005;<span class="ref-vol">33</span>:D433–D437. doi: 10.1093/nar/gki005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC539959/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15608232" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fnar%2Fgki005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res.&amp;title=STRING:+Known+and+predicted+protein-protein+associations,+integrated+and+transferred+across+organisms&amp;author=C.+Von+Mering&amp;author=L.J.+Jensen&amp;author=B.+Snel&amp;author=S.D.+Hooper&amp;author=M.+Krupp&amp;volume=33&amp;publication_year=2005&amp;pages=D433-D437&amp;pmid=15608232&amp;doi=10.1093/nar/gki005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B72-ijms-24-09943">72. <span class="element-citation">Huber W., von Heydebreck A., S&#x000fc;ltmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. <span><span class="ref-journal">Bioinformatics. </span>2002;<span class="ref-vol">18</span>((Suppl. S1)):S96–S104. doi: 10.1093/bioinformatics/18.suppl_1.S96.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12169536" ref="reftype=pubmed&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fbioinformatics%2F18.suppl_1.S96" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Variance+stabilization+applied+to+microarray+data+calibration+and+to+the+quantification+of+differential+expression&amp;author=W.+Huber&amp;author=A.+von+Heydebreck&amp;author=H.+S&#x000fc;ltmann&amp;author=A.+Poustka&amp;author=M.+Vingron&amp;volume=18&amp;issue=(Suppl.+S1)&amp;publication_year=2002&amp;pages=S96-S104&amp;pmid=12169536&amp;doi=10.1093/bioinformatics/18.suppl_1.S96&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10298070&amp;issue-id=439230&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">International Journal of Molecular Sciences</span> are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10298070/pdf/ijms-24-09943.pdf" class="int-view">PDF (3.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10298070/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10298070/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10298070" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="gIflmTFVHUF0XOshNJiFn99hFDpc6xrdGqWGr2pV3PEXC1iDD5QcJeOrCVubZf50">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F&amp;text=Upregulated%20Expression%20of%20ERBB2%2FHER2%20in%20Multiple%20Myeloma%20as%20a%20Predictor%20of%20Poor%20Survival%20Outcomes" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10298070%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298070/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37373090/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37373090/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10298070/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10298070/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10298070/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
